US20160084572A1 - Process control methods for obtaining and maintaining a desired moisture content of spray dried plasma - Google Patents

Process control methods for obtaining and maintaining a desired moisture content of spray dried plasma Download PDF

Info

Publication number
US20160084572A1
US20160084572A1 US14/858,517 US201514858517A US2016084572A1 US 20160084572 A1 US20160084572 A1 US 20160084572A1 US 201514858517 A US201514858517 A US 201514858517A US 2016084572 A1 US2016084572 A1 US 2016084572A1
Authority
US
United States
Prior art keywords
drying
plasma
spray
temperature
drying gas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/858,517
Inventor
Abdul Wahid Khan
Michael Wilt
Rud Karly Lucien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZymeQuest Inc
Original Assignee
ZymeQuest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZymeQuest Inc filed Critical ZymeQuest Inc
Priority to US14/858,517 priority Critical patent/US20160084572A1/en
Publication of US20160084572A1 publication Critical patent/US20160084572A1/en
Assigned to VELICO MEDICAL, INC. reassignment VELICO MEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KHAN, ABDUL WAHID, LUCIEN, RUD KARLY, WILT, MICHAEL
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/06Solidifying liquids
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B3/00Drying solid materials or objects by processes involving the application of heat
    • F26B3/02Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air
    • F26B3/04Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the gas or vapour circulating over or surrounding the materials or objects to be dried
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B3/00Drying solid materials or objects by processes involving the application of heat
    • F26B3/02Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air
    • F26B3/06Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the gas or vapour flowing through the materials or objects to be dried
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B3/00Drying solid materials or objects by processes involving the application of heat
    • F26B3/02Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air
    • F26B3/10Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the gas or vapour carrying the materials or objects to be dried with it
    • F26B3/12Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the gas or vapour carrying the materials or objects to be dried with it in the form of a spray, i.e. sprayed or dispersed emulsions or suspensions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00049Controlling or regulating processes
    • B01J2219/00177Controlling or regulating processes controlling the pH
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00Closures not otherwise provided for
    • B65D51/24Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
    • B65D51/28Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
    • B65D51/30Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials for desiccators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • F26B5/065Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing the product to be freeze-dried being sprayed, dispersed or pulverised

Definitions

  • blood plasma is a whole blood component in which blood cells and other constituents of whole blood are suspended. Blood plasma further contains a mixture of over 700 proteins and additional substances that perform functions necessary for bodily health, including clotting, protein storage, and electrolytic balance, amongst others. When extracted from whole blood, blood plasma may be employed to replace bodily fluids, antibodies and clotting factors. Accordingly, blood plasma is extensively used in medical treatments.
  • Spray drying is a process wherein a liquid containing solutes such as proteins and salts is aerosolized into small droplets. The moisture is then evaporated out of the aerosolized droplets with heated air or other gas, allowing constituents to precipitate into a powder or powder-like form.
  • the dried powder may contain from 2% to 10% or more moisture, depending on the nature of the precipitant(s) and desired goal of the process. Thus, “dried” or “dry” is a relative term and not an absolute term. Over drying may damage the sought-after precipitant(s) while under drying can leave the precipitant too moist resulting clumping or caking and degradation of the precipitant(s) during storage.
  • problems associated with the spray drying process include obtaining and maintaining a suitable drying process to ensure the desired dryness is obtained while not over drying or under drying the sought-after precipitant.
  • Current technologies utilize intricate arrays of temperature and moisture sensors, the data from which a person or computer analyzes before making any necessary adjustments to the spray dry process. Constant monitoring and adjustment is necessary because, throughout the spray drying process, the temperature and moisture levels in the drying chamber are constantly changing as moisture is released from the aerosolized droplets. The relative complexity of these systems can result in errors in analysis or errors in the multitude of possible adjustments that can be made. Human plasma is a valuable commodity and obtaining active, stable plasma proteins in reconstituted spray dried plasma is a precise process.
  • a long-standing need and challenge to the blood industry has been to provide safe, reliable and convenient blood products while preserving the efficacy and safety of those products in storage and when used in transfusion or as a source a medical treatments.
  • the efficient and efficacious production of these products is the important first step in meeting this need and challenge.
  • the present invention provides for efficient methods and processes for the spray drying of human plasma that are superior to the prior art methods with regard to providing a consistent product with negligible areas for generating process errors.
  • the present invention contemplates a spray drying control process and procedure that solves the problems associated with prior art spray drying control processes and procedures, especially with regard to the spray drying of human plasma.
  • the inventors of the present invention have discovered that the spray drying process can be controlled effectively, and spray dried human plasma with active plasma proteins recovered, by measuring the exhaust gas temperature of the spray dryer during the spray drying process, and adjusting the flow rate of the drying gas to maintain the desired exhaust gas temperature.
  • increasing the flow rate of the drying gas puts more heat into the drying chamber, increases the exhaust gas temperature and decreases the moisture content of the spray dried plasma; and decreasing the drying gas flow decreases the heat put into the drying chamber, decreases the exhaust gas temperature and increases the moisture content of the spray dried plasma.
  • the inventors have found that adjusting and maintaining the exhaust gas temperature by changing the flow rate of the drying gas rather than changing the temperature of the drying gas results in a faster response rate since the flow of the drying gas can be changed almost instantaneously whereas changing the temperature of the drying gas would require a time lag for warming or cooling the gas. Further, an exhaust gas temperature of approximately 50° C. to 65° C. has been found to be suitable for obtaining the desired spray dried plasma moisture content. Further still, the exhaust gas temperature of approximately 55° C. has been found to be most suitable for obtaining the desired spray dried plasma moisture content. The desired moisture content of the spray dried plasma is about 4% to about 10%.
  • the process and method of the present invention may utilize electronic or computerized control mechanisms for reading the exhaust gas temperature and calculating the necessary adjustment to the drying gas flow rate.
  • Embodiments of suitable software code will be apparent to those of skill in the art in view of the teachings of this specification. In still other embodiments, it is contemplated that the adjustments are made manually by a trained operator.
  • the present invention contemplates a method of controlling the moisture content of a spray dried plasma.
  • the method comprises: providing: i) plasma and ii) a spray drying apparatus.
  • the spray dry apparatus comprises a mechanism for aerosolizing the plasma, a mechanism to deliver drying gas at a controlled rate, a drying chamber, a collection chamber and a sensor for measuring exhaust gas temperature as it emerges from the drying process
  • the method further comprises operating the spray drying apparatus to produce a moisture controlled spray dried plasma, the operation comprising controlling the moisture content of the spray dried plasma collected in the collection chamber by measuring the exhaust gas temperature with the sensor for measuring exhaust gas temperature and adjusting the flow of the drying gas based on the exhaust gas temperature wherein the flow of the drying gas is increased to increase the exhaust gas temperature and decrease the moisture content of the spray dried plasma; and the drying gas flow is decreased to decrease the exhaust gas temperature and increase the moisture content of the spray dried plasma.
  • This method produces a moisture controlled spray dried plasma having a moisture content of approximately 4 w/w % to approximately 10 w/w
  • the present invention further contemplates that the moisture content of the moisture controlled spray dried plasma is approximately 4 w/w % to approximately 8 w/w %.
  • the present invention still further contemplates that the exhaust gas temperature is maintained at a set point in the range of from approximately 45° C. to approximately 65° C.
  • the present invention still further contemplates that the exhaust gas temperature is maintained at a set point in the range of from approximately 50° C. to approximately 60° C.
  • the present invention still further contemplates that the exhaust gas temperature is maintained at a set point of approximately 55° C.
  • the present invention still further contemplates that the drying gas has a temperature of about 100° C.-150° C. when it starts to mix with the aerosolized plasma.
  • the present invention still further contemplates that the drying gas flow is maintained at approximately 500 L/min to approximately 1000 L/min during the process for producing the moisture controlled spray dried plasma.
  • the present invention still further contemplates that the drying process is controlled by a computer.
  • the present invention still further contemplates that the flow rate of the drying gas flow rate and percent moisture of the moisture controlled spry dried plasma is based on previously collected data.
  • the present invention still further contemplates that the plasma is whole blood (WB) plasma or citrate phosphate dextrose (CPD) plasma.
  • WB whole blood
  • CPD citrate phosphate dextrose
  • FIG. 1A is a schematic illustration of an embodiment of a spray dryer system of the present disclosure, including a spray dryer device 102 and a spray dryer assembly.
  • FIG. 1B is a schematic illustration of a plurality of the spray dryer systems of FIG. 1A for use with a pooled liquid source.
  • FIGS. 2A and 2B are schematic illustrations of the spray dryer assembly of FIG. 1A .
  • FIG. 3 is a schematic illustration detailing embodiments of a collection chamber of the spray dryer assembly of FIGS. 2A-2B .
  • FIG. 4 panels A-C are schematic illustrations depicting unfolding/refolding model of the vWF A2 domain and protelolysis by ADAMTS13.
  • A Cartoon of the vWF A2 domain in its native folded state.
  • B The first step of unfolding occurs from the C-terminal end of the vWF A2 domain, influenced by the presence of the vicinal disulphide bond (cysteines depicted by C). Initial unfolding occurs up to, or including, the central b4 sheet in which the scissile bond (YM) is contained. This unfolding intermediate step exposes the high-affinity ADAMTS13 spacer-binding site.
  • C Once the stabilizing effect of the CBS is overcome this results in the complete unfolding of the vWF A2 domain and the positioning of the ADAMTS13 active site for nucleophilic attack of the Y1605-M1606 scissile bond.
  • FIG. 5 shows a schematic diagram of an embodiment of the computer hardware of the suitable for use in the present invention.
  • FIG. 6 shows a schematic diagram of an embodiment of the automation flow of the software of the present invention.
  • FIG. 7 shows a schematic diagram of an embodiment of the flow of the drying progress of the present invention.
  • FIG. 8 shows a schematic diagram of an embodiment of the product flow of the present invention up to the drying apparatus. Symbols and designations are explained in the Detailed Description, below.
  • FIG. 9 shows a schematic diagram of an embodiment of the product flow of the present invention from to the drying apparatus. Symbols and designations are explained in the Detailed Description, below.
  • FIG. 10 shows a schematic diagram of an embodiment of a spray dryer with a mechanical collection filter for use in the present invention.
  • FIG. 11 shows a schematic diagram of two views of an embodiment of a spray dryer with a removable/disposable collection filter bag for use in the present invention.
  • the left hand drawing indicates where various temperatures are measured.
  • the right hand drawing indicates the designation of the various temperature sensors. Measurements are approximate.
  • FIG. 12 shows results of a study on degradation of protein activity in relation to spray dryer temperature.
  • the X-axis is the collection chamber temperature (° C.).
  • the Y-axis is normalized protein activity for fibrinogen and factor X.
  • FIG. 13 is a graphical representation of a product run showing consistent temperature readings at the dryer inlet, the collection bag inlet and the collection bag exhaust.
  • FIG. 14 is a graphical representation of a product run showing consistent temperature readings at the dryer inlet, the collection bag inlet and the collection bag exhaust.
  • FIG. 15 is a graphical representation of a product run showing consistent temperature readings at the dryer inlet, the collection bag inlet and the collection bag exhaust.
  • FIG. 16 shows the combined results of multiple product runs. Exhaust gas temperature is on the X-axis. Residual moisture is on the Y-axis. The graph shows that temperatures between about 50° C. and 60° C. produce product dried to about 4.8% to about 6.0% residual moisture with 55° C. producing product with about 5.0% residual moisture.
  • Embodiments of the present disclosure are directed to systems and methods for spray drying a liquid sample.
  • the liquid sample is plasma obtained from a blood donor.
  • the blood donor is human.
  • the disclosed embodiments may be employed to spray dry any biological mixture of solid particles and/or molecules in a continuous liquid medium, including, but not limited to, colloids, suspensions and sols.
  • Plasma is the fluid that remains after blood has been centrifuged (for example) to remove cellular materials such as red blood cells, white blood cells and platelets. Plasma is generally yellow-colored and clear to opaque. It contains the dissolved constituents of the blood such as dissolved proteins (6-8%; i.e., serum albumins, globulins, fibrinogen, etc.), glucose, clotting factors (clotting proteins), electrolytes (Na + , Ca 2+ , Mg 2+ , HCO 3 ⁇ , Cl ⁇ , etc.), hormones, etc.
  • Whole blood (WB) plasma is plasma isolated from whole blood with no added agents except anticoagulant(s).
  • Citrate phosphate dextrose (CPD) plasma contains citrate, sodium phosphate and a sugar, usually dextrose, which are added for stability and as anticoagulants.
  • the level of citrate in CPD plasma is typically about 20-30 mM.
  • the plasma of the present invention may be dried after pooling or unit-by-unit. Pooling of multiple plasma units has some benefits. For example, any shortfall in factor recovery on an equal-volume basis can be made up by adding volume from the pool to the finished product. There are negative factors as well. Making up volume from the pool to improve factor recovery is expensive. Importantly, pooled plasma must be constantly tested for pathogens as any pathogens entering the pool runs the risk of harming hundreds or thousands of patients if not detected. Even if detected, pathogen contamination of pooled plasma would render the whole pool valueless. Testing can be obviated by pathogen inactivation of the plasma by irradiation or chemically such as solvent detergent treatment; however, each such treatment adds cost and complexity to pooled plasma processing. In any event, pooled plasma processing is generally unsuitable to the blood centers and generally only really suitable to an industrial, mass production environment.
  • unit-by-unit (unit) collection and processing is well-suited to the blood center and eliminates the risk of pooled plasma pathogen contamination by allowing for pre-processing testing for pathogens and tracking of the unit to ensure that each unit leaves the blood center site pathogen free.
  • the inventors have discovered that efficient and effective preservation and recovery of clotting factors is the standard by which successful unit blood plasma processing should be measured. Such efficiency is also very helpful in the pooled plasma environment as well.
  • the present invention is primarily directed towards unit-by-unit drying of plasma.
  • the methods and compositions of the present invention include recovering amounts of active/undenatured FGN, F V, F VII, F IX and von Willebrand factor (vWF) from rehydrated plasma that has undergone the spray drying process.
  • Such blood plasma factors are important in patient treatment, especially after trauma injuries, to promote clotting of wounds. Thus, rapid administration of plasma is often needed to be performed quickly.
  • the spray dried plasma of the present invention is ideal in that it can be readily reconstituted in a few minutes at the location of the trauma event without moving the patient and without time delay. Further, the spray dried plasma of the present invention has high levels of functional protein that is stable for extended periods of time without refrigeration or freezing.
  • vWF has generally been difficult to recover and has become one indicator for preservation of all factors. In an embodiment, if vWF is preserved, the other factors are likely to be preserved as well.
  • the present invention includes recovering amounts of active/undenatured clotting factors, such as vWF, in an amount in rehydrated spray dried plasma that is at least about 20 percentage points or greater (e.g., about 30, 40 50, 60, 70, 80 percentage points or greater) as compared to amounts of active/undenatured clotting factors (i.e., vWF) of rehydrated spray dried plasma that do not undergo the processes of the present invention.
  • the present invention includes recovering amounts of active/undenatured clotting factors, such as vWF, in an amount in rehydrated spray dried plasma that is at about 20 percentage points to about 40 percentage points or about 25 percentage points to about 35 percentage points as compared to amounts of active/undenatured clotting factors (i.e., vWF) of rehydrated spray dried plasma that do not undergo the processes of the present invention.
  • vWF activity is typically assayed with an assay called the von Willebrand factor: Ristocetin cofactor [vWF:RCo] assay, as is known to those of skill in the art.
  • the vWF:RCo assay measures the ability of a patient's plasma to agglutinate platelets in the presence of the antibiotic Ristocetin.
  • the rate of Ristocetin induced agglutination is related to the concentration and functional activity of the plasma von Willebrand factor.
  • Another assay, the vWF antigen assay measures the amount of vWF present in a sample.
  • vWF is a large adhesive glycoprotein with established functions in hemostasis. It serves as a carrier for factor VIII and acts as a vascular damage sensor by attracting platelets to sites of vessel injury.
  • the size of vWF is important for this latter function, with larger multimers being more hemostatically active. Functional imbalance in multimer size can variously cause microvascular thrombosis or bleeding.
  • ADAMTS13 a plasma metalloprotease that is constitutively active. It is secreted into blood and degrades large vWF multimers, decreasing their activity.
  • ADAMTS13 protease activity of ADAMTS13 is controlled not by natural inhibitors but by conformational changes in its substrate, which are induced when vWF is subject to elevated rheologic shear forces. This transforms vWF from a globular to an elongated protein. This conformational transformation unfolds the vWF A2 domain and reveals cryptic exosites as well as the scissile bond.
  • ADAMTS13 makes multiple interactions that bring the protease to the substrate and position it to engage with the cleavage site as this becomes exposed by shear forces (See, FIG. 4 ).
  • ADAMTS 13 a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), also known as von Willebrand factor-cleaving protease (vWFCP), is a zinc-containing metalloprotease enzyme.
  • temperatures and moisture are related parameters. Higher drying temperatures result in lower moisture levels and lower drying temperatures result in higher moisture levels.
  • temperatures that are too high, while resulting in drier spray dried powders may cause irreversible damage to the constituents of the powder, especially proteins, thereby reducing recovery of active product.
  • temperatures that are too low, while resulting in less damage to product may leave the moisture content too high leading to clumping, caking and the degradation of constituents causing decreases in long term stability of the product.
  • the optimal balance must be obtained to provide a powder that is dry enough to reduce moisture related stability issues and temperatures that are low enough to permit the highest recovery of active product.
  • Prior art methods of dealing with the regulation of heat and moisture in a spray dryer often utilized multiple temperature, moisture and flow sensors. Data from these sensors would then be feed into either a computer that would change process parameters based on computer coding, or be feed to various readout devices such as charts and gauges, where an operator would make process adjustments based on written protocol and experience. Because of the large number of sensors used, the plethora of possible combinations of adjustments that could be made, many of which would counteract other adjustments, production errors could be frequent and could result in substandard, wasted product.
  • the present invention eliminates these concerns by using only one reading to regulate the spray dry process so that the desired product moisture level is obtained at the temperature that is most advantageous for the recovery and stability of active protein product.
  • the exhaust temperature of the spray dry process is measured at the exit of the collection chamber (see, below for a description of an embodiment of a spray dryer apparatus suitable for spray drying human plasma). Based on this temperature, the drying gas flow rate is maintained, increased or decreased such that the target exhaust gas temperature is obtained.
  • any means known to those of ordinary skill in the art for the introduction and regulation of a flow of gas is contemplated for use with the present invention with regard to introducing and regulating the drying gas flow.
  • the desired exhaust gas temperature is about 50° C. to about 60° C.
  • the exhaust gas temperature is about 55° C. It is further contemplated that the exhaust gas temperature is increased or decreased by changing the flow rate of the drying gas. If an increase in the exhaust gas temperature is desired, the flow of the drying gas is increased. If a decrease of the temperature of the exhaust gas is desired, the flow rate of the drying gas is decreased. Increased flow rate of the drying gas results in a greater input of heated gas into the drying chamber of the spray dryer apparatus. This in turn results in a decrease in the moisture content of the spray dried product. Decreased flow rate of the drying gas results in a lower input of heated gas into the drying chamber of the spray dryer apparatus. This in turn results in an increase in the moisture content of the spray dried product.
  • the desired moisture content of spray dried human plasma is about 3% to about 10% or about 4% to about 6%.
  • the present invention has found that an exhaust gas temperature of about 55° C. is suitable to obtain this level of moisture in the spray dried human plasma product.
  • the drying gas flow is maintained at approximately 550 L/minute to approximately 750 L/minute during the process for producing the moisture controlled spray dried plasma.
  • the regulation of the flow rate of the drying gas is controlled by an automated feedback control loop integrated with the temperature of the exhaust gas and the automated feedback control loop is controlled by a computer.
  • the flow rate of the drying gas flow rate and percent moisture of the moisture controlled spry dried plasma is based on previously collected data.
  • a spray dryer system for spray drying a liquid sample such as blood plasma.
  • the spray dryer system of the present disclosure includes a spray dryer device and a spray dryer assembly.
  • the spray dryer device is adapted, in an aspect, to receive flows of an aerosolizing gas, a drying gas and plasma liquid from respective sources and coupled with the spray dryer assembly.
  • the spray dryer device may further transmit the received aerosolizing gas, drying gas and plasma to the spray dryer assembly.
  • Spray drying of the plasma is performed in the spray dryer assembly under the control of the spray dryer device.
  • Any suitable spray drying system may be used in the present invention.
  • a suitable spray dryer is described below.
  • the spray dryer assembly includes a sterile, hermetically sealed enclosure body and a frame to which the enclosure body is attached.
  • the frame defines first, second and third portions of the assembly, separated by respective transition zones.
  • a drying gas inlet is provided within the first portion of the assembly adjacent to a first end of the enclosure body.
  • a spray drying head is further attached to the frame within the transition zone between the first and second portions of the assembly. This position also lies within the incipient flow path of the drying gas within the assembly.
  • the spray drying head receives flows of an aerosolizing gas and plasma and aerosolizes the plasma with the aerosolizing gas to form aerosolized plasma.
  • Drying gas additionally passes through the spray drying head to mix with the aerosolized plasma within the second portion of the assembly for drying.
  • contact between the aerosolized plasma and the drying gas causes moisture to move from the aerosolized plasma to the drying gas, producing dried plasma and humid drying gas.
  • the aerosolizing gas may be omitted and the spray dryer assembly head may include an aerosolizer that receives and atomizes the flow of plasma.
  • the aerosolizer may include, but are not limited to, ultrasonic atomizing transducers, ultrasonic humidifier transducers, and piezo-ultrasonic atomizers.
  • the aerosolizer may include, but are not limited to, ultrasonic atomizing transducers, ultrasonic humidifier transducers, and piezo-ultrasonic atomizers.
  • such a configuration eliminates the need for an aerosolizing gas, simplifying the design of the spray dryer device and assembly.
  • the spray drying head in an embodiment, is adapted to direct the flow of drying gas within the drying chamber.
  • the spray drying head includes openings separated by fins which receive the flow of drying gas from the drying gas inlet.
  • the orientation of the fins allows the drying gas to be directed in selected flow pathways (e.g., helical).
  • selected flow pathways e.g., helical.
  • the dried plasma and humid drying gas subsequently flow into the third portion of assembly, which houses a collection chamber.
  • the dried plasma is isolated from the humid drying gas and collected using a filter.
  • the filter in an embodiment of the invention is open on one side to receive the flow of humid air and dried plasma and closed on the remaining sides.
  • the humid drying gas passes through the filter and is exhausted from the spray dryer assembly.
  • the filter is adapted to separate the collection chamber into two parts.
  • the first part of the collection chamber is contiguous with the drying chamber and receives the flow of humid drying gas and dried plasma.
  • the dried plasma is collected in this first part of the collection chamber, while the humid air passes through the filter and is exhausted from the spray dryer assembly via an exhaust in fluid communication with the second part of the spray dryer assembly.
  • the collection chamber After collecting the dried plasma, the collection chamber is separated from the spray dryer assembly and hermetically sealed. In this manner, the sealed collection chamber is used to store the dried plasma until use.
  • the collection chamber includes a plurality of ports allowing addition of water to the collection chamber for reconstitution of the blood plasma and removal of the reconstituted blood plasma for use.
  • the collection chamber may further be attached to a sealed vessel containing water for reconstitution.
  • the spray dryer assembly in an embodiment, is adapted for reversible coupling with the spray dryer device.
  • the spray dryer assembly is coupled to the spray dryer device at about the drying gas inlet.
  • the spray dryer assembly accommodates repeated or single use.
  • the spray dryer assembly and spray drying head is formed from autoclavable materials (e.g., steels, alloys, etc.) that are sterilized prior to each spray drying operation.
  • the spray dryer head and spray drying chamber is formed from disposable materials (e.g., polymers) that are autoclaved prior to each spray drying operation and disposed of after each spray drying operation.
  • FIG. 1A schematically illustrates one embodiment of a spray dryer system 100 .
  • the system 100 includes a spray dryer device 102 configured to receive a spray dryer assembly 104 .
  • a source of plasma 112 , a source of aerosolizing gas 114 , and a source of drying gas 116 are further in fluid communication with the spray dryer assembly 104 .
  • a flow of the drying gas 116 A is drawn within the body of the assembly 104 .
  • a flow of a blood plasma 112 A and a flow of aerosolizing gas 114 A are each drawn at selected, respective rates, to a spray drying head 104 A of the assembly 104 .
  • the flow of blood plasma 112 A is aerosolized in the spray dryer head 104 A and dried in a drying chamber 104 B, producing a dried plasma that is collected and stored for future use in a collection chamber 104 C. Waste water 122 removed from the blood plasma during the drying process is further collected for appropriate disposal.
  • the spray dryer device 102 further includes a spray dryer computing device 124 .
  • the spray dryer computing device 124 is adapted to monitor and control a plurality of process parameters of the spray drying operation.
  • the spray dryer computing device 124 further includes a plurality of user interfaces.
  • one user interface may allow an operator to input data (e.g., operator information, liquid sample information, dried sample information, etc.), command functions (e.g., start, stop, etc.).
  • Another user interface may display status information regarding components of the spray drier device (e.g., operating normally, replace, etc.) and/or spray drying process information (e.g., ready, in-process, completed, error, etc.).
  • the spray dryer device 102 records one or more parameters associated with a spray drying operation. Examples of these parameters includes, but are not limited to, bibliographic information regarding the blood plasma which is spray dried (e.g., lot number, collection date, volume, etc.), bibliographic information regarding the spray drying operation (e.g., operator, date of spray drying, serial number of the spray dryer assembly 104 , volume of dried plasma, etc.), process parameters (e.g., flow rates, temperatures, etc.).
  • the spray dryer device 102 Upon completion of a spray drying operation, the spray dryer device 102 communicates a selected portion or all the collected information to the blood bank computer system or other suitable computing device 150 .
  • a spray drying system 100 may be housed in a blood bank facility.
  • the blood back facility receives regular blood donations for storage. Liquid plasma is separated from whole blood donations, dried using the spray drying system 100 and subsequently stored until use.
  • a plurality of spray dryer systems 100 A, 1008 , . . . 100 N can be used in combination with a pooled plasma source 112 ′.
  • the pooled plasma source 112 ′ is a bulk source of blood plasma having a volume larger than one blood unit, as known in the art (e.g., approximately 1 pint or 450 mL).
  • Two or more of the spray dryer systems 100 A, 1008 . . . 100 N can operate concurrently, each drawing blood for spray drying from the pooled plasma source 112 ′, rather than a smaller, local blood source.
  • the spray dryer systems 100 A, 1008 . . . 100 N in a pooled environment can operate under the control of a computing device 124 ′.
  • the computing device 124 ′ is similar to computing device 124 discussed above, but adapted for concurrent control of each of the spray dryer systems 100 A, 1008 . . . 100 N.
  • the spray dryer computing device 124 ′ further communicates with a remote computing device 150 , as also discussed above.
  • pooled plasma source 112 ′ provides advantages over a smaller, local plasma source, such as plasma source 112 .
  • the pooled liquid plasma can be treated for pathogen inactivation with UV light, a chemical, and the like.
  • the pooled liquid plasma is dried using one or more spray drying systems 100 of the present invention and then the dried plasma can be collect in a single collection chamber or a plurality of collection chambers. If the pooled plasma is dried for human transfusion, then each collection container can be configured with an attached rehydration solution. If the pooled plasma is to be used for fractionation purposes, then it is collected in a configured without the rehydration solution.
  • FIG. 2A and 2B illustrate embodiments of the spray dryer assembly 104 in greater detail.
  • the spray dryer assembly 104 includes a frame 202 .
  • An enclosure or body 204 having first and second ends 208 A & 208 B further extends about and encloses the frame 202 .
  • the body 204 adopts the shape of the frame 202 .
  • the enclosure 204 may further include a dual layer of film sealed together about the periphery of the frame 202 .
  • the frame 202 may define a first portion 206 A, a second portion 206 B, and a third portion 206 C of the assembly 104 .
  • the first portion of the assembly 206 A is positioned adjacent the first end 208 A of the body 204 .
  • the third portion of the assembly 206 C is positioned adjacent to the second end 208 B of the enclosure 204 .
  • the second portion of the assembly 206 B is interposed between the first and third portions of the assembly 206 A, 206 C.
  • the frame 202 further defines first and second transition zones 210 A, 210 B between the first, second, and third portions of the assembly 206 A, 206 B, 206 C.
  • first transition zone 210 A may be positioned between the first and second portions of the assembly 206 A, 206 B and the second transition zone 210 B may be positioned between the second and third portions of the assembly 206 B, 206 C.
  • the frame 202 may narrow in width, as compared to the width of the surrounding assembly within the transition zones 210 A, and/or 210 B. The relatively narrow transition zones 210 A, 210 B help to direct the flow of drying gas 116 A through the assembly 104 .
  • the body 204 may include a drying gas inlet 212 , adjacent to the first end 208 A.
  • the drying gas inlet 212 may be adapted to couple with the spray dryer device 102 to form a hermetic and sterile connection that allows the flow of drying gas 116 A to enter the assembly 104 .
  • the drying gas inlet 212 is positioned within the first portion of the assembly 206 A, at about the terminus of the first end of the body 208 A. In this configuration, the flow of drying gas 116 A is received within the assembly 104 in a direction approximately parallel to a long axis 250 of the assembly 104 .
  • the body 204 may include a drying gas inlet 212 ′.
  • the position of the drying gas inlet 212 ′ is moved with respect to drying gas inlet 212 .
  • the drying gas inlet 212 ′ may be positioned within the first portion of the assembly 206 A and spaced a selected distance from the terminus of the first end of the enclosure 208 A.
  • the flow of drying gas 116 A may be received within the assembly 104 in a direction that is not parallel to the long axis 250 of the assembly 104 .
  • the flow of drying gas 116 A is received within the assembly 104 in a direction that is approximately perpendicular to the long axis 250 of the assembly 104 .
  • the spray dryer assembly 104 may further include a removable cover 218 .
  • the cover 218 may be employed prior to coupling of the spray dryer assembly 104 with the spray drier device 102 in order to inhibit contaminants from entering the spray dryer assembly. In certain embodiments, the cover 218 may be removed immediately prior to coupling with the spray dryer device 102 or frangible and penetrated by the spray dryer device 102 during coupling with the spray dryer assembly 104 .
  • the drying gas 116 A received by the assembly 104 is urged to travel from the first portion 206 A, through the second portion 206 B, to the third portion 206 C, where it is removed from the assembly 104 .
  • the drying gas 116 A passes through a first filter 220 A which filters the drying gas 116 A entering the assembly 104 in addition to any filtering taking place within the spray dryer device 102 between the drying gas source 116 and the drying gas inlet 212 .
  • the first filter 220 A is a 0.2 micron filter having a minimum BFE (bacterial filter efficiency) of 10 6 .
  • the filter 220 A further helps to ensure the cleanliness of the flow of drying gas 116 A.
  • the flow of drying gas BFE received by the spray drier assembly BFE may possess a temperature between about 50° C. and about 150° C. and a flow rate of between about 15 CFM to about 35 CFM.
  • the flow of aerosolizing gas 116 A can possess a flow rate of between about 5 L/min and about 20 L/min and a temperature between about 15° C. to about 30° C. (e.g., 24° C.).
  • the flow of liquid sample 112 A may possess a flow rate of between about 3 ml/min to about 20 ml/min.
  • the flow of the aerosolizing gas 114 A, the flow of drying gas 116 C, or both may direct the flow of the dried sample 232 through at least a portion of the spray dryer assembly 104 (e.g., the drying chamber, the collection chamber or both).
  • the assembly 104 may further include a spray drying head 104 A, a drying chamber 104 B, and a collection chamber 104 C in fluid communication with one another.
  • the spray drying head 104 A may be mounted to the frame 202 and positioned within the first transition zone 210 A. So positioned, the spray drying head 104 A is also positioned within the flow of drying gas 116 A traveling from the first portion of the assembly 206 A to the second portion of the assembly 206 B.
  • the spray drying head 104 A may be further adapted to receive the flow of plasma 112 A and the flow of aerosolizing gas 114 A through respective feed lines 214 , 216 and output aerosolized plasma 230 to the drying chamber 104 B.
  • the drying chamber 104 B and collection chamber 104 C may be positioned within the second and third portions of the assembly 206 B, 206 C, respectively.
  • the drying chamber 1048 inflates under the pressure of the flow of drying gas 116 A and provides space for the aerosolized blood plasma 230 and the flow of drying gas 116 A to contact one another.
  • moisture is transferred from the aerosolized blood plasma 230 to the drying gas 116 A, where the drying gas 116 A becomes humid drying gas 234 .
  • the aerosolized flow of blood plasma 230 and the flow of drying gas 116 A are further separated, within the drying chamber 104 B, into dried plasma 232 and humid drying gas 234 .
  • the dried plasma 232 may possess a mean diameter of less than or equal to 25 ⁇ m.
  • the humid drying gas 234 and dried plasma 232 are further drawn into the collection chamber 104 C through an inlet port 222 A of the collection chamber 104 C, positioned within the second transition zone 210 B, connecting the collection chamber 104 C and the drying chamber 104 B.
  • the collection chamber 104 includes a second filter 220 B which allows through-passage of the humid drying gas 234 and inhibits through-passage of the dried plasma 232 .
  • the humid drying gas 234 passing through the filter 220 B is separated from the dried plasma 232 and exhausted from the collection bag 104 C through an exhaust port 222 B of the collection chamber 104 C that forms the second end 208 B of the body 204 .
  • a vacuum source e.g., a vacuum pump
  • a vacuum source may be in fluid communication with the exhaust port 222 B of the collection chamber 104 C to urge the humid drying gas 234 through exhaust port b.
  • the dried plasma 232 is retained in a reservoir 228 of the collection chamber 104 C.
  • the collection chamber 104 C is subsequently hermetically sealed at about the inlet and exhaust ports 222 A, 222 B, and detached (e.g., cut) from the spray dryer assembly 104 , allowing the collection chamber 104 C to subsequently function as a storage vessel for the dried plasma 232 until use.
  • the collection chamber 104 C further includes a plurality of one-way valves 702 A, 702 B positioned at about the inlet port 222 A and the exhaust port 222 B, respectively.
  • the one-way valve 702 A may function to permit gas flow from the drying chamber 104 B to the collection chamber 104 C and inhibit gas flow from the collection chamber 104 C to the drying chamber 104 B.
  • the one-way valve 702 B may function to permit gas flow from the collection chamber 104 C while inhibiting gas flow into the collection chamber 104 C via the exhaust port 222 B.
  • the collection chamber 104 C may be further configured for use in rehydrating the dried plasma 232 .
  • the collection chamber 104 C may include a rehydration port 224 , a plurality of spike ports 226 , and a vent port 228 .
  • the rehydration port 224 may be used to communicate with a source of rehydration solution, allowing the rehydration solution to come in contact with the dried plasma 232 within the collection chamber 104 C to form reconstituted plasma.
  • the reconstituted plasma may be subsequently drawn from the collection chamber 104 C through the spike ports 226 .
  • the temperature of the collection chamber 104 C may be regulated by measuring the temperature of the humid exhaust gas 234 A as it exits the collection chamber 104 C.
  • One or more of the flow rate of the drying gas 116 A, and the temperature of the drying gas 116 A may be adjusted, based upon the temperature of the humid exhaust gas 234 A, to maintain the collection chamber 104 C at temperatures less than about 70° C. and preferably at about 50° C. to about 60° C. or about 55° C.
  • the Spray-Dry Plasma (SpDP) control system runs on a small computer capable of running, for example, the open-source Linux operating system.
  • This computer is connected to a LabJack U6 I/O controller via USB.
  • This computer is connected via Ethernet to all external systems including a computer used to provide the web-based user interface.
  • the automation software is responsible for controlling the spray-dry process.
  • the master state machine controls the sequence of operations required to conduct the drying process.
  • the update cycle runs at approximately 10 Hz. During each update the values of the sensors are read, the control system computations are executed, and the new output values are written out. Data is logged to an internal database which may be accessed by the blood center computer systems and/or the web user interface described next.
  • the user interface to the spray-dry instrument is implemented as web pages served by the automation computer. Any computer running a web browser may be used to access the user interface pages provided the user authentication is successful.
  • Self-Test In the self-test state the operating system is booted up and diagnostic tests are performed to ensure that the hardware is functioning correctly.
  • Disposable Integrity Test Once the disposable (the disposable comprises a self-contained spray dry chamber and product collection bag) has been loaded the system conducts an integrity test to ensure that the disposable is loaded properly and not leaking.
  • the dryer drains are closed
  • the drying gas flow rates is set for drying and the controller is enabled
  • the heater controller set point is set for drying and the controller is enabled.
  • the aerosol gas flow rate is set for drying.
  • Drying gas temperature more than 85% of the target temperature for drying. Drying gas flow rate more than 85% of the target flow rate for drying. Start-up Exhaust temperature observed by T5 more than 65° C.
  • the peristaltic pump flow rate is set to half of the value which will be used for drying.
  • Fluid Half-Speed In this state the fluid is running at half the rate which will be used for drying. To move onto the next state the drying gas temperature must be as the target set point for drying.
  • Fluid Full-Speed This is the primary state for drying the full unit of plasma. The scale value is monitored and when the full unit has been processed the state moves forward to the Finished state.
  • the peristaltic pump is switched to reverse to back the plasma away from the spray nozzle and prevent dripping of liquid plasma into the dry product.
  • Controllers All of the controllers except the peristaltic pump controller use a PID
  • Aerosol The aerosol controller maintains a flow set point by monitoring the flow sensor F1 and controlling the PWM duty cycle to the variable valve V2.
  • the aerosol controller also maintains pressure in the pneumatic reservoir by controlling the aerosol gas pump and the soft-start valve V5.
  • a feed-forward term is used to compensate for the changing pressure observed at P1, which goes up quickly when the aerosol gas pump is running and drops slowly when the aerosol gas pump is off.
  • the drying gas controller maintains a flow set point by monitoring the flow sensor F2 and controlling the analog voltage to the drying gas pump motor controller.
  • the heater controller maintains a temperature set point for the drying gas by monitoring the temperature sensor T5 and modulating the power to the heater.
  • the heater power is modulated with a duty cycle of approximately 1 Hz to provide reasonably good time resolution with the heater power switching on zero crossings at the 60 Hz (or 50 Hz) power line frequency.
  • the peristaltic pump controller transforms the commanded flow rate to an analog voltage command for the pump controller.
  • the forward/reverse line is controlled based on the sign of the flow rate.
  • a negative flow rate can be used to back up the pump and prevent liquid from dripping out of the spray nozzle at the end of the drying cycle.
  • the brake is set when the flow rate is zero to completely stop the pump.
  • Exhaust Gas The exhaust gas controller maintains a set exhaust temperature by monitoring the temperature sensor T6 and adjusting the set point of the drying gas flow controller. A higher flow rate results in a higher exhaust temperature. The flow rate is controlled rather than the drying gas temperature because it is much quicker to respond as necessary to maintain the exhaust gas temperature set point.
  • the error value used by this controller is the difference between the exhaust gas temperature observed at T6 and the set point (° C.).
  • the controller determines an offset to apply to the drying gas flow rate set point.
  • the gains used by the controller are:
  • the output of this controller is limited to the range ⁇ 150.0L/min to +150.0 L/min adjustment to the commanded flow rate.
  • the error integrator is saturated at a value that would maximize the controller output. This prevents the integrator from winding up significantly when the controller is unable to achieve the set point.
  • Web Pages and Data Flow The user interface web pages are generated by cgi programs written in C++. Communication between these user interface web pages and the automation software is accomplished using POSIX queues. The automation software creates the queues and publishes the data while the system is running to the monitor queues. It also listens for input from the user interface on the command queues.
  • the automated drying user interface contains the minimal controls and status information required by an operator to conduct the drying process.
  • Diagnostics The diagnostics user interface shows all of the sensor values and controller set points in real time while the system is operating. This facilitates process development and diagnosis of hardware issues.
  • the data access user interface allows downloading of data stored in the automation computer database.
  • the drying gas control system takes air from outside environment and conditions it for use as drying gas.
  • the air is filtered, dehumidified and heated as it is pumped at a controlled flow rate through the system.
  • the specific components in this flow path are:
  • the spray-dry process requires consistent flow and temperature of the drying gas so both of these attributes are actively controlled.
  • the drying gas flow rate is measured by the flow sensor F2 and a feedback loop controls the motor speed to achieve the correct drying gas flow rate.
  • the temperature is measured by the temperature sensor T5 and a feedback loop controls the heater power to achieve the correct drying gas temperature.
  • the drying gas leaving the disposable contains all of the moisture that was evaporated from the plasma.
  • the exhaust gas management system incorporates a second dehumidifier to remove this moisture.
  • the exhaust gas management system also incorporates a back-up filter and instrumentation to monitor the performance of the drying process.
  • the specific components in this flow path are:
  • the spray-dry unit has mechanical features to facilitate hanging the incoming plasma unit, mounting the drying disposable, loading and clamping the plasma tube in the peristaltic pump, and removing the disposable components after the drying process is completed.
  • the disposable drying chamber has connections at the top for the plasma feed, aerosol gas feed, and drying gas feed. It has a connection at the bottom for the exhaust gas.
  • the system constrains the disposable so it may inflate only to the volume required by the drying process. This minimizes the mechanical strength required of the disposable, allowing the use of a relatively thin material which may soften somewhat during the drying process without losing its integrity and leaking.
  • the heater assembly is comprised primarily of stainless steel for strength and heat resistance. This structure has a relatively large thermal mass so it takes some time to come up to operating temperature or cool back down to the temperature of the ambient environment. This heat-up and cool-down time is decoupled from the processing cycle by leaving the heater assembly hot while the disposable is changed between cycles. There is a thermal break between the heater and the disposable interface so the operator is not exposed to hot surfaces that are unsafe to touch between cycles.
  • Drying Instrument Filters The filters incorporated into the drying instrument provide an additional level of protection for the plasma being processed.
  • the air used for drying gas is cleaned before it enters the disposable.
  • the drying disposable incorporates its own additional filtering.
  • the region of the instrument where the disposable docking is performed is additionally protected by filtered laminar air flow to significantly reduce any bio-burden that might be introduced while docking the disposable.
  • Service Interface The system is designed to facilitate routine maintenance by trained personnel at the customer facility.
  • HEPA filters which are incorporated into the device are designed to be changed by trained service personnel as necessary.
  • the drying system monitors pressure drops across the filters and reports to the operator when a filter needs to be changed.
  • Ranges of values include all values within the range not specifically mentioned. For example, a range of “20% or greater” includes all values from 20% to 100% including 35%, 41.6%, 67.009%, etc., even though those values are not specifically mentioned.
  • drying gas exhaust temperature the most important parameter with respect to protein viability in dried plasma was the drying gas exhaust temperature. If dried plasma is exposed to an exhaust temperature higher than 60° C., even briefly, plasma protein activity degrades. Please note, during the drying process the surface of the wet plasma droplets is exposed to 125° C. but the droplet remains cool due to the evaporation process. A significant improvement in process consistency was achieved by actively controlling the exhaust temperature by varying the speed of the drying gas pump and, thus, the flow rate of the drying gas through the spray drying apparatus.
  • the body When bleeding occurs, the body causes coagulation factors, such as Fibrinogen and/or Factor V, to combine and produce a clot which stops bleeding. Insufficient protein activity may impair clot formation, resulting in excessive bleeding. Accordingly, it is desirable that the protein activity of dried plasma is relatively unchanged as compared to its liquid state. When these blood proteins are damaged, such as by exposure to elevated temperature during plasma drying, measured protein activity is reduced.
  • coagulation factors such as Fibrinogen and/or Factor V
  • FIG. 12 represents the ratio of the protein activity of dried plasma to the protein activity of the liquid plasma and may vary between 1.0 to 0. High values of normalized protein activity, approaching 1.0, indicate that the proteins within the dried plasma are relatively undamaged, as compared to the liquid plasma. In contrast, low values of normalized protein activity, approaching 0, indicate that the proteins within the dried plasma are relatively damaged, as compared to the liquid plasma.
  • FIG. 12 plots the normalized protein activity as a function of temperature within the range between 55° C. to 70° C.
  • collection chamber temperature correlates with collection bag exhaust temperature and is about 3° C. higher than the exhaust temperature.
  • collection bag temperature and collection bag exhaust temperature are proxies for each other.
  • FIG. 12 shows that protein activity increases for each of Fibrinogen and Factor V as the collection chamber temperature decreases from about 70° C. to about 55° C.
  • the normalized activity of Fibrinogen increases from about 0.60 to about 0.925, while the normalized activity of Factor V increases from about 0.83 to about 0.97 over this range. Accordingly, embodiments of the drying processes discussed herein should be performed such that the temperature of the collection chamber is about 55° C.
  • Plasma fluid flow rate 10 mL/minute
  • Aerosol gas flow rate 20 L/minute
  • Drying gas initial temperature 125° C.
  • Drying gas exhaust temperature 52° C.
  • the exhaust gas temperature was maintained at about 52° C. by varying the drying gas flow rate.
  • temperature probes were placed at the drying head, the inlet of the collection filter bag and at the exhaust of the collection filter bag.
  • temperature sensor T5 measures the inlet drying gas temperature
  • temperature sensor T8 measures the inlet collection filter bag temperature
  • temperature sensor T6 measures the exhaust gas temperature as it leaves the collection filter bag.
  • Pressure sensor P7 measures the pressure generated during the spray drying process. The temperature difference between the T5 and T8 temperature sensors shows the temperature drop caused by the drying process and released of moisture from the aerosolized plasma droplets.
  • FIGS. 13 , 14 and 15 show the results of three separate experiments. The results show that by maintaining the exhaust gas temperature as a constant 52° C., the temperature at the drying gas inlet and at the inlet of the collection filter bag were also constant.
  • Spray dryer parameters used were
  • Exhaust gas temperature was controlled at various temperatures from 30° C. to 70° C. Residual moisture in the dried plasma was measured by the Karl Fisher method for dried plasma collected in the collection filter.
  • FIG. 16 shows the residual moisture content of the dried plasma ranged from about 15% when the exhaust temperature was maintained at about 30° C. to about 4.0% when the exhaust temperature was maintained at about 70° C.
  • the spray drier was operated to keep the exhaust gas temperature from about 55-60° C.
  • the plasma protein activity was measured to be within 15% of the native protein.
  • preferred residual moisture content of from about 4% to about 6% was obtained when the exhaust gas temperature was maintained from about 60° C. to about 52° C., respectively.
  • the present invention contemplates operating the spray drier apparatus so that the exhaust gas temperature ranges from about 52° C. to about 60° C. with the preferred exhaust gas temperature being from 54° C. to 58° C. or about 55° C.
  • Example 3 When taken together, the results of Examples 1, 2 and Example 3 show that maintaining the exhaust gas temperature at a predetermined temperature (temperature range) results in a suitably dried plasma powder with acceptable plasma protein activity recovery.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

A method of controlling the moisture content of a spray dried product by measuring the drying gas flow exhaust temperature and adjusting the drying gas flow rate to maintain a predetermined exhaust temperature that results in the production of a spray dried product with a desired moisture content. A preferred product is spray dried human plasma.

Description

    GOVERNMENT SUPPORT
  • This invention was made with Government support under contract HS0100201200005C awarded by the Biomedical Advanced Research and Development Authority (BARDA). The Government has certain rights in the invention.
  • BACKGROUND
  • Making up about 55% of the total volume of whole blood, blood plasma is a whole blood component in which blood cells and other constituents of whole blood are suspended. Blood plasma further contains a mixture of over 700 proteins and additional substances that perform functions necessary for bodily health, including clotting, protein storage, and electrolytic balance, amongst others. When extracted from whole blood, blood plasma may be employed to replace bodily fluids, antibodies and clotting factors. Accordingly, blood plasma is extensively used in medical treatments.
  • Spray drying is a process wherein a liquid containing solutes such as proteins and salts is aerosolized into small droplets. The moisture is then evaporated out of the aerosolized droplets with heated air or other gas, allowing constituents to precipitate into a powder or powder-like form. The dried powder may contain from 2% to 10% or more moisture, depending on the nature of the precipitant(s) and desired goal of the process. Thus, “dried” or “dry” is a relative term and not an absolute term. Over drying may damage the sought-after precipitant(s) while under drying can leave the precipitant too moist resulting clumping or caking and degradation of the precipitant(s) during storage. Consequently, problems associated with the spray drying process include obtaining and maintaining a suitable drying process to ensure the desired dryness is obtained while not over drying or under drying the sought-after precipitant. Current technologies utilize intricate arrays of temperature and moisture sensors, the data from which a person or computer analyzes before making any necessary adjustments to the spray dry process. Constant monitoring and adjustment is necessary because, throughout the spray drying process, the temperature and moisture levels in the drying chamber are constantly changing as moisture is released from the aerosolized droplets. The relative complexity of these systems can result in errors in analysis or errors in the multitude of possible adjustments that can be made. Human plasma is a valuable commodity and obtaining active, stable plasma proteins in reconstituted spray dried plasma is a precise process. Incorrectly spray dried plasma cannot be reconstituted and re-dried because repeating the process would greatly decrease the recovery and stability of any plasma proteins. Therefore, there is only one chance to dry any lot of plasma correctly. Thus, errors in the spray drying of human plasma that result in over dried, under dried or over heated plasma must be minimized or avoided.
  • Accordingly, there is a need to develop simpler techniques and processes for the control of the spray dry process, especially for the spray drying of human plasma.
  • SUMMARY
  • A long-standing need and challenge to the blood industry has been to provide safe, reliable and convenient blood products while preserving the efficacy and safety of those products in storage and when used in transfusion or as a source a medical treatments. The efficient and efficacious production of these products is the important first step in meeting this need and challenge. The present invention provides for efficient methods and processes for the spray drying of human plasma that are superior to the prior art methods with regard to providing a consistent product with negligible areas for generating process errors.
  • The present invention contemplates a spray drying control process and procedure that solves the problems associated with prior art spray drying control processes and procedures, especially with regard to the spray drying of human plasma. The inventors of the present invention have discovered that the spray drying process can be controlled effectively, and spray dried human plasma with active plasma proteins recovered, by measuring the exhaust gas temperature of the spray dryer during the spray drying process, and adjusting the flow rate of the drying gas to maintain the desired exhaust gas temperature. In this regard, increasing the flow rate of the drying gas puts more heat into the drying chamber, increases the exhaust gas temperature and decreases the moisture content of the spray dried plasma; and decreasing the drying gas flow decreases the heat put into the drying chamber, decreases the exhaust gas temperature and increases the moisture content of the spray dried plasma. The inventors have found that adjusting and maintaining the exhaust gas temperature by changing the flow rate of the drying gas rather than changing the temperature of the drying gas results in a faster response rate since the flow of the drying gas can be changed almost instantaneously whereas changing the temperature of the drying gas would require a time lag for warming or cooling the gas. Further, an exhaust gas temperature of approximately 50° C. to 65° C. has been found to be suitable for obtaining the desired spray dried plasma moisture content. Further still, the exhaust gas temperature of approximately 55° C. has been found to be most suitable for obtaining the desired spray dried plasma moisture content. The desired moisture content of the spray dried plasma is about 4% to about 10%.
  • The process and method of the present invention may utilize electronic or computerized control mechanisms for reading the exhaust gas temperature and calculating the necessary adjustment to the drying gas flow rate. Embodiments of suitable software code will be apparent to those of skill in the art in view of the teachings of this specification. In still other embodiments, it is contemplated that the adjustments are made manually by a trained operator.
  • The present invention contemplates a method of controlling the moisture content of a spray dried plasma. The method comprises: providing: i) plasma and ii) a spray drying apparatus. The spray dry apparatus comprises a mechanism for aerosolizing the plasma, a mechanism to deliver drying gas at a controlled rate, a drying chamber, a collection chamber and a sensor for measuring exhaust gas temperature as it emerges from the drying process The method further comprises operating the spray drying apparatus to produce a moisture controlled spray dried plasma, the operation comprising controlling the moisture content of the spray dried plasma collected in the collection chamber by measuring the exhaust gas temperature with the sensor for measuring exhaust gas temperature and adjusting the flow of the drying gas based on the exhaust gas temperature wherein the flow of the drying gas is increased to increase the exhaust gas temperature and decrease the moisture content of the spray dried plasma; and the drying gas flow is decreased to decrease the exhaust gas temperature and increase the moisture content of the spray dried plasma. This method produces a moisture controlled spray dried plasma having a moisture content of approximately 4 w/w % to approximately 10 w/w %.
  • The present invention further contemplates that the moisture content of the moisture controlled spray dried plasma is approximately 4 w/w % to approximately 8 w/w %.
  • The present invention still further contemplates that the exhaust gas temperature is maintained at a set point in the range of from approximately 45° C. to approximately 65° C.
  • The present invention still further contemplates that the exhaust gas temperature is maintained at a set point in the range of from approximately 50° C. to approximately 60° C.
  • The present invention still further contemplates that the exhaust gas temperature is maintained at a set point of approximately 55° C.
  • The present invention still further contemplates that the drying gas has a temperature of about 100° C.-150° C. when it starts to mix with the aerosolized plasma.
  • The present invention still further contemplates that the drying gas flow is maintained at approximately 500 L/min to approximately 1000 L/min during the process for producing the moisture controlled spray dried plasma.
  • The present invention still further contemplates that the drying process is controlled by a computer.
  • The present invention still further contemplates that the flow rate of the drying gas flow rate and percent moisture of the moisture controlled spry dried plasma is based on previously collected data.
  • The present invention still further contemplates that the plasma is whole blood (WB) plasma or citrate phosphate dextrose (CPD) plasma.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The foregoing and other objects, features and advantages will be apparent from the following more particular description of the embodiments, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the embodiments.
  • FIG. 1A is a schematic illustration of an embodiment of a spray dryer system of the present disclosure, including a spray dryer device 102 and a spray dryer assembly.
  • FIG. 1B is a schematic illustration of a plurality of the spray dryer systems of FIG. 1A for use with a pooled liquid source.
  • FIGS. 2A and 2B are schematic illustrations of the spray dryer assembly of FIG. 1A.
  • FIG. 3 is a schematic illustration detailing embodiments of a collection chamber of the spray dryer assembly of FIGS. 2A-2B.
  • FIG. 4 panels A-C are schematic illustrations depicting unfolding/refolding model of the vWF A2 domain and protelolysis by ADAMTS13. (A) Cartoon of the vWF A2 domain in its native folded state. (B) The first step of unfolding occurs from the C-terminal end of the vWF A2 domain, influenced by the presence of the vicinal disulphide bond (cysteines depicted by C). Initial unfolding occurs up to, or including, the central b4 sheet in which the scissile bond (YM) is contained. This unfolding intermediate step exposes the high-affinity ADAMTS13 spacer-binding site. (C) Once the stabilizing effect of the CBS is overcome this results in the complete unfolding of the vWF A2 domain and the positioning of the ADAMTS13 active site for nucleophilic attack of the Y1605-M1606 scissile bond.
  • FIG. 5 shows a schematic diagram of an embodiment of the computer hardware of the suitable for use in the present invention.
  • FIG. 6 shows a schematic diagram of an embodiment of the automation flow of the software of the present invention.
  • FIG. 7 shows a schematic diagram of an embodiment of the flow of the drying progress of the present invention.
  • FIG. 8 shows a schematic diagram of an embodiment of the product flow of the present invention up to the drying apparatus. Symbols and designations are explained in the Detailed Description, below.
  • FIG. 9 shows a schematic diagram of an embodiment of the product flow of the present invention from to the drying apparatus. Symbols and designations are explained in the Detailed Description, below.
  • FIG. 10 shows a schematic diagram of an embodiment of a spray dryer with a mechanical collection filter for use in the present invention.
  • FIG. 11 shows a schematic diagram of two views of an embodiment of a spray dryer with a removable/disposable collection filter bag for use in the present invention. The left hand drawing indicates where various temperatures are measured. The right hand drawing indicates the designation of the various temperature sensors. Measurements are approximate.
  • FIG. 12 shows results of a study on degradation of protein activity in relation to spray dryer temperature. The X-axis is the collection chamber temperature (° C.). The Y-axis is normalized protein activity for fibrinogen and factor X.
  • FIG. 13 is a graphical representation of a product run showing consistent temperature readings at the dryer inlet, the collection bag inlet and the collection bag exhaust.
  • FIG. 14 is a graphical representation of a product run showing consistent temperature readings at the dryer inlet, the collection bag inlet and the collection bag exhaust.
  • FIG. 15 is a graphical representation of a product run showing consistent temperature readings at the dryer inlet, the collection bag inlet and the collection bag exhaust.
  • FIG. 16 shows the combined results of multiple product runs. Exhaust gas temperature is on the X-axis. Residual moisture is on the Y-axis. The graph shows that temperatures between about 50° C. and 60° C. produce product dried to about 4.8% to about 6.0% residual moisture with 55° C. producing product with about 5.0% residual moisture.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Embodiments of the present disclosure are directed to systems and methods for spray drying a liquid sample. In certain embodiments, the liquid sample is plasma obtained from a blood donor. In a preferred embodiment, the blood donor is human. However, it may be understood that the disclosed embodiments may be employed to spray dry any biological mixture of solid particles and/or molecules in a continuous liquid medium, including, but not limited to, colloids, suspensions and sols.
  • Plasma
  • Plasma is the fluid that remains after blood has been centrifuged (for example) to remove cellular materials such as red blood cells, white blood cells and platelets. Plasma is generally yellow-colored and clear to opaque. It contains the dissolved constituents of the blood such as dissolved proteins (6-8%; i.e., serum albumins, globulins, fibrinogen, etc.), glucose, clotting factors (clotting proteins), electrolytes (Na+, Ca2+, Mg2+, HCO3 , Cl, etc.), hormones, etc. Whole blood (WB) plasma is plasma isolated from whole blood with no added agents except anticoagulant(s). Citrate phosphate dextrose (CPD) plasma, as the name indicates, contains citrate, sodium phosphate and a sugar, usually dextrose, which are added for stability and as anticoagulants. The level of citrate in CPD plasma is typically about 20-30 mM.
  • The plasma of the present invention may be dried after pooling or unit-by-unit. Pooling of multiple plasma units has some benefits. For example, any shortfall in factor recovery on an equal-volume basis can be made up by adding volume from the pool to the finished product. There are negative factors as well. Making up volume from the pool to improve factor recovery is expensive. Importantly, pooled plasma must be constantly tested for pathogens as any pathogens entering the pool runs the risk of harming hundreds or thousands of patients if not detected. Even if detected, pathogen contamination of pooled plasma would render the whole pool valueless. Testing can be obviated by pathogen inactivation of the plasma by irradiation or chemically such as solvent detergent treatment; however, each such treatment adds cost and complexity to pooled plasma processing. In any event, pooled plasma processing is generally unsuitable to the blood centers and generally only really suitable to an industrial, mass production environment.
  • Conversely, unit-by-unit (unit) collection and processing is well-suited to the blood center and eliminates the risk of pooled plasma pathogen contamination by allowing for pre-processing testing for pathogens and tracking of the unit to ensure that each unit leaves the blood center site pathogen free. The inventors have discovered that efficient and effective preservation and recovery of clotting factors is the standard by which successful unit blood plasma processing should be measured. Such efficiency is also very helpful in the pooled plasma environment as well. The present invention is primarily directed towards unit-by-unit drying of plasma.
  • Clotting Factors
  • There are many blood plasma factors associated with clotting. The methods and compositions of the present invention include recovering amounts of active/undenatured FGN, F V, F VII, F IX and von Willebrand factor (vWF) from rehydrated plasma that has undergone the spray drying process. Such blood plasma factors are important in patient treatment, especially after trauma injuries, to promote clotting of wounds. Thus, rapid administration of plasma is often needed to be performed quickly. The spray dried plasma of the present invention is ideal in that it can be readily reconstituted in a few minutes at the location of the trauma event without moving the patient and without time delay. Further, the spray dried plasma of the present invention has high levels of functional protein that is stable for extended periods of time without refrigeration or freezing.
  • vWF has generally been difficult to recover and has become one indicator for preservation of all factors. In an embodiment, if vWF is preserved, the other factors are likely to be preserved as well. The present invention includes recovering amounts of active/undenatured clotting factors, such as vWF, in an amount in rehydrated spray dried plasma that is at least about 20 percentage points or greater (e.g., about 30, 40 50, 60, 70, 80 percentage points or greater) as compared to amounts of active/undenatured clotting factors (i.e., vWF) of rehydrated spray dried plasma that do not undergo the processes of the present invention. The present invention includes recovering amounts of active/undenatured clotting factors, such as vWF, in an amount in rehydrated spray dried plasma that is at about 20 percentage points to about 40 percentage points or about 25 percentage points to about 35 percentage points as compared to amounts of active/undenatured clotting factors (i.e., vWF) of rehydrated spray dried plasma that do not undergo the processes of the present invention. vWF activity is typically assayed with an assay called the von Willebrand factor: Ristocetin cofactor [vWF:RCo] assay, as is known to those of skill in the art. The vWF:RCo assay measures the ability of a patient's plasma to agglutinate platelets in the presence of the antibiotic Ristocetin. The rate of Ristocetin induced agglutination is related to the concentration and functional activity of the plasma von Willebrand factor. Another assay, the vWF antigen assay, measures the amount of vWF present in a sample.
  • vWF is a large adhesive glycoprotein with established functions in hemostasis. It serves as a carrier for factor VIII and acts as a vascular damage sensor by attracting platelets to sites of vessel injury. The size of vWF is important for this latter function, with larger multimers being more hemostatically active. Functional imbalance in multimer size can variously cause microvascular thrombosis or bleeding. The regulation of vWF multimeric size and platelet-tethering function is carried out by ADAMTS13, a plasma metalloprotease that is constitutively active. It is secreted into blood and degrades large vWF multimers, decreasing their activity. Unusually, protease activity of ADAMTS13 is controlled not by natural inhibitors but by conformational changes in its substrate, which are induced when vWF is subject to elevated rheologic shear forces. This transforms vWF from a globular to an elongated protein. This conformational transformation unfolds the vWF A2 domain and reveals cryptic exosites as well as the scissile bond. To enable vWF proteolysis, ADAMTS13 makes multiple interactions that bring the protease to the substrate and position it to engage with the cleavage site as this becomes exposed by shear forces (See, FIG. 4). ADAMTS 13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), also known as von Willebrand factor-cleaving protease (vWFCP), is a zinc-containing metalloprotease enzyme.
  • Temperature and Moisture Control of the Drying Process
  • During the spray drying process temperature and moisture are related parameters. Higher drying temperatures result in lower moisture levels and lower drying temperatures result in higher moisture levels. However, the use of temperatures that are too high, while resulting in drier spray dried powders (i.e., powders with lower moisture content), may cause irreversible damage to the constituents of the powder, especially proteins, thereby reducing recovery of active product. Conversely, the use of temperatures that are too low, while resulting in less damage to product, may leave the moisture content too high leading to clumping, caking and the degradation of constituents causing decreases in long term stability of the product. Thus, the optimal balance must be obtained to provide a powder that is dry enough to reduce moisture related stability issues and temperatures that are low enough to permit the highest recovery of active product. This balancing act is complicated by the fact that moisture and temperature levels in the spray dryer are constantly in flux, at least to a small extent, as the liquid (e.g., plasma) to be dried and heated drying gas are forced into the dryer. This is particularly true during the start and end of the product run.
  • Prior art methods of dealing with the regulation of heat and moisture in a spray dryer often utilized multiple temperature, moisture and flow sensors. Data from these sensors would then be feed into either a computer that would change process parameters based on computer coding, or be feed to various readout devices such as charts and gauges, where an operator would make process adjustments based on written protocol and experience. Because of the large number of sensors used, the plethora of possible combinations of adjustments that could be made, many of which would counteract other adjustments, production errors could be frequent and could result in substandard, wasted product.
  • The present invention eliminates these concerns by using only one reading to regulate the spray dry process so that the desired product moisture level is obtained at the temperature that is most advantageous for the recovery and stability of active protein product. In the present invention, the exhaust temperature of the spray dry process is measured at the exit of the collection chamber (see, below for a description of an embodiment of a spray dryer apparatus suitable for spray drying human plasma). Based on this temperature, the drying gas flow rate is maintained, increased or decreased such that the target exhaust gas temperature is obtained. In this regard, any means known to those of ordinary skill in the art for the introduction and regulation of a flow of gas is contemplated for use with the present invention with regard to introducing and regulating the drying gas flow. In an embodiment, it is contemplated that the desired exhaust gas temperature is about 50° C. to about 60° C. In an embodiment, it is contemplated that the exhaust gas temperature is about 55° C. It is further contemplated that the exhaust gas temperature is increased or decreased by changing the flow rate of the drying gas. If an increase in the exhaust gas temperature is desired, the flow of the drying gas is increased. If a decrease of the temperature of the exhaust gas is desired, the flow rate of the drying gas is decreased. Increased flow rate of the drying gas results in a greater input of heated gas into the drying chamber of the spray dryer apparatus. This in turn results in a decrease in the moisture content of the spray dried product. Decreased flow rate of the drying gas results in a lower input of heated gas into the drying chamber of the spray dryer apparatus. This in turn results in an increase in the moisture content of the spray dried product. The desired moisture content of spray dried human plasma is about 3% to about 10% or about 4% to about 6%. The present invention has found that an exhaust gas temperature of about 55° C. is suitable to obtain this level of moisture in the spray dried human plasma product.
  • In an embodiment, the drying gas flow is maintained at approximately 550 L/minute to approximately 750 L/minute during the process for producing the moisture controlled spray dried plasma.
  • In an embodiment, the regulation of the flow rate of the drying gas is controlled by an automated feedback control loop integrated with the temperature of the exhaust gas and the automated feedback control loop is controlled by a computer.
  • In an embodiment, the flow rate of the drying gas flow rate and percent moisture of the moisture controlled spry dried plasma is based on previously collected data.
  • Spray Dryer and the Spray Drying Process
  • In general, a spray dryer system (spray dryer device) is provided for spray drying a liquid sample such as blood plasma. In an embodiment, the spray dryer system of the present disclosure includes a spray dryer device and a spray dryer assembly. The spray dryer device is adapted, in an aspect, to receive flows of an aerosolizing gas, a drying gas and plasma liquid from respective sources and coupled with the spray dryer assembly. The spray dryer device may further transmit the received aerosolizing gas, drying gas and plasma to the spray dryer assembly. Spray drying of the plasma is performed in the spray dryer assembly under the control of the spray dryer device. Any suitable spray drying system may be used in the present invention. For exemplification, a suitable spray dryer is described below.
  • In certain embodiments, the spray dryer assembly includes a sterile, hermetically sealed enclosure body and a frame to which the enclosure body is attached. The frame defines first, second and third portions of the assembly, separated by respective transition zones. A drying gas inlet is provided within the first portion of the assembly adjacent to a first end of the enclosure body.
  • A spray drying head is further attached to the frame within the transition zone between the first and second portions of the assembly. This position also lies within the incipient flow path of the drying gas within the assembly. During spray drying, the spray drying head receives flows of an aerosolizing gas and plasma and aerosolizes the plasma with the aerosolizing gas to form aerosolized plasma. Drying gas additionally passes through the spray drying head to mix with the aerosolized plasma within the second portion of the assembly for drying. In the second portion of the assembly, which functions as a drying chamber, contact between the aerosolized plasma and the drying gas causes moisture to move from the aerosolized plasma to the drying gas, producing dried plasma and humid drying gas.
  • In alternative embodiments, the aerosolizing gas may be omitted and the spray dryer assembly head may include an aerosolizer that receives and atomizes the flow of plasma. Examples of the aerosolizer may include, but are not limited to, ultrasonic atomizing transducers, ultrasonic humidifier transducers, and piezo-ultrasonic atomizers. Beneficially, such a configuration eliminates the need for an aerosolizing gas, simplifying the design of the spray dryer device and assembly.
  • The spray drying head, in an embodiment, is adapted to direct the flow of drying gas within the drying chamber. For example, the spray drying head includes openings separated by fins which receive the flow of drying gas from the drying gas inlet. The orientation of the fins allows the drying gas to be directed in selected flow pathways (e.g., helical). Beneficially, by controlling the flow pathway of the drying gas, the path length over which the drying gas and aerosolized blood plasma are in contact within the drying chamber can be increased, reducing the time to dry the plasma.
  • The dried plasma and humid drying gas subsequently flow into the third portion of assembly, which houses a collection chamber. In the collection chamber, the dried plasma is isolated from the humid drying gas and collected using a filter. For example, the filter in an embodiment of the invention is open on one side to receive the flow of humid air and dried plasma and closed on the remaining sides. The humid drying gas passes through the filter and is exhausted from the spray dryer assembly.
  • In alternative embodiments, the filter is adapted to separate the collection chamber into two parts. The first part of the collection chamber is contiguous with the drying chamber and receives the flow of humid drying gas and dried plasma. The dried plasma is collected in this first part of the collection chamber, while the humid air passes through the filter and is exhausted from the spray dryer assembly via an exhaust in fluid communication with the second part of the spray dryer assembly.
  • After collecting the dried plasma, the collection chamber is separated from the spray dryer assembly and hermetically sealed. In this manner, the sealed collection chamber is used to store the dried plasma until use. The collection chamber includes a plurality of ports allowing addition of water to the collection chamber for reconstitution of the blood plasma and removal of the reconstituted blood plasma for use. The collection chamber may further be attached to a sealed vessel containing water for reconstitution.
  • When handling transfusion products such as blood plasma, the transfusion products must not be exposed to any contaminants during collection, storage, and transfusion. Accordingly, the spray dryer assembly, in an embodiment, is adapted for reversible coupling with the spray dryer device. For example, the spray dryer assembly is coupled to the spray dryer device at about the drying gas inlet. Beneficially, so configured, the spray dryer assembly accommodates repeated or single use. For example, in one embodiment, the spray dryer assembly and spray drying head is formed from autoclavable materials (e.g., steels, alloys, etc.) that are sterilized prior to each spray drying operation. In an alternative embodiment, the spray dryer head and spray drying chamber is formed from disposable materials (e.g., polymers) that are autoclaved prior to each spray drying operation and disposed of after each spray drying operation.
  • Reference will now be made to FIG. 1A, which schematically illustrates one embodiment of a spray dryer system 100. The system 100 includes a spray dryer device 102 configured to receive a spray dryer assembly 104. A source of plasma 112, a source of aerosolizing gas 114, and a source of drying gas 116 are further in fluid communication with the spray dryer assembly 104. During spray drying operations, a flow of the drying gas 116A is drawn within the body of the assembly 104. Concurrently, a flow of a blood plasma 112A and a flow of aerosolizing gas 114A are each drawn at selected, respective rates, to a spray drying head 104A of the assembly 104. In the spray dryer assembly 104, the flow of blood plasma 112A is aerosolized in the spray dryer head 104A and dried in a drying chamber 104B, producing a dried plasma that is collected and stored for future use in a collection chamber 104C. Waste water 122 removed from the blood plasma during the drying process is further collected for appropriate disposal.
  • The spray dryer device 102 further includes a spray dryer computing device 124.
  • The spray dryer computing device 124 is adapted to monitor and control a plurality of process parameters of the spray drying operation. The spray dryer computing device 124 further includes a plurality of user interfaces. For example, one user interface may allow an operator to input data (e.g., operator information, liquid sample information, dried sample information, etc.), command functions (e.g., start, stop, etc.). Another user interface may display status information regarding components of the spray drier device (e.g., operating normally, replace, etc.) and/or spray drying process information (e.g., ready, in-process, completed, error, etc.).
  • The spray dryer device 102 records one or more parameters associated with a spray drying operation. Examples of these parameters includes, but are not limited to, bibliographic information regarding the blood plasma which is spray dried (e.g., lot number, collection date, volume, etc.), bibliographic information regarding the spray drying operation (e.g., operator, date of spray drying, serial number of the spray dryer assembly 104, volume of dried plasma, etc.), process parameters (e.g., flow rates, temperatures, etc.). Upon completion of a spray drying operation, the spray dryer device 102 communicates a selected portion or all the collected information to the blood bank computer system or other suitable computing device 150.
  • For example, a spray drying system 100 may be housed in a blood bank facility. The blood back facility receives regular blood donations for storage. Liquid plasma is separated from whole blood donations, dried using the spray drying system 100 and subsequently stored until use.
  • In an alternative embodiment, illustrated in FIG. 1B, a plurality of spray dryer systems 100A, 1008, . . . 100N can be used in combination with a pooled plasma source 112′. In general, the pooled plasma source 112′ is a bulk source of blood plasma having a volume larger than one blood unit, as known in the art (e.g., approximately 1 pint or 450 mL). Two or more of the spray dryer systems 100A, 1008 . . . 100N can operate concurrently, each drawing blood for spray drying from the pooled plasma source 112′, rather than a smaller, local blood source.
  • The spray dryer systems 100A, 1008 . . . 100N in a pooled environment can operate under the control of a computing device 124′. The computing device 124′ is similar to computing device 124 discussed above, but adapted for concurrent control of each of the spray dryer systems 100A, 1008 . . . 100N. The spray dryer computing device 124′ further communicates with a remote computing device 150, as also discussed above.
  • The use of a pooled plasma source 112′, provides advantages over a smaller, local plasma source, such as plasma source 112. When pooled prior to drying, the pooled liquid plasma can be treated for pathogen inactivation with UV light, a chemical, and the like. The pooled liquid plasma is dried using one or more spray drying systems 100 of the present invention and then the dried plasma can be collect in a single collection chamber or a plurality of collection chambers. If the pooled plasma is dried for human transfusion, then each collection container can be configured with an attached rehydration solution. If the pooled plasma is to be used for fractionation purposes, then it is collected in a configured without the rehydration solution. Further embodiments of a spray dryer device 102 for use with the disclosed spray dryer assembly 104 may be found in U.S. patent application Ser. No. 13/952,541, filed on Jul. 26, 2013 and entitled “Automated Spray dryer,” the entirety of which is hereby incorporated by reference.
  • FIG. 2A and 2B illustrate embodiments of the spray dryer assembly 104 in greater detail. As illustrated in FIG. 2A, the spray dryer assembly 104 includes a frame 202. An enclosure or body 204 having first and second ends 208A & 208B further extends about and encloses the frame 202. Thus, the body 204 adopts the shape of the frame 202. The enclosure 204 may further include a dual layer of film sealed together about the periphery of the frame 202.
  • In certain embodiments, the frame 202 may define a first portion 206A, a second portion 206B, and a third portion 206C of the assembly 104. The first portion of the assembly 206A is positioned adjacent the first end 208A of the body 204. The third portion of the assembly 206C is positioned adjacent to the second end 208B of the enclosure 204. The second portion of the assembly 206B is interposed between the first and third portions of the assembly 206A, 206C.
  • The frame 202 further defines first and second transition zones 210A, 210B between the first, second, and third portions of the assembly 206A, 206B, 206C. For example, the first transition zone 210A may be positioned between the first and second portions of the assembly 206A, 206B and the second transition zone 210B may be positioned between the second and third portions of the assembly 206B, 206C. In certain embodiments, the frame 202 may narrow in width, as compared to the width of the surrounding assembly within the transition zones 210A, and/or 210B. The relatively narrow transition zones 210A, 210B help to direct the flow of drying gas 116A through the assembly 104.
  • In further embodiments, the body 204 may include a drying gas inlet 212, adjacent to the first end 208A. The drying gas inlet 212 may be adapted to couple with the spray dryer device 102 to form a hermetic and sterile connection that allows the flow of drying gas 116A to enter the assembly 104. In one embodiment, illustrated in FIG. 2A, the drying gas inlet 212 is positioned within the first portion of the assembly 206A, at about the terminus of the first end of the body 208A. In this configuration, the flow of drying gas 116A is received within the assembly 104 in a direction approximately parallel to a long axis 250 of the assembly 104.
  • In an alternative embodiment of the spray dryer assembly 104, illustrated in FIG. 2B, the body 204 may include a drying gas inlet 212′. The position of the drying gas inlet 212′ is moved with respect to drying gas inlet 212. For example, the drying gas inlet 212′ may be positioned within the first portion of the assembly 206A and spaced a selected distance from the terminus of the first end of the enclosure 208A. In this configuration, the flow of drying gas 116A may be received within the assembly 104 in a direction that is not parallel to the long axis 250 of the assembly 104. For example, in a non-limiting embodiment, the flow of drying gas 116A is received within the assembly 104 in a direction that is approximately perpendicular to the long axis 250 of the assembly 104.
  • In certain embodiments, the spray dryer assembly 104 may further include a removable cover 218. The cover 218 may be employed prior to coupling of the spray dryer assembly 104 with the spray drier device 102 in order to inhibit contaminants from entering the spray dryer assembly. In certain embodiments, the cover 218 may be removed immediately prior to coupling with the spray dryer device 102 or frangible and penetrated by the spray dryer device 102 during coupling with the spray dryer assembly 104.
  • The drying gas 116A received by the assembly 104 is urged to travel from the first portion 206A, through the second portion 206B, to the third portion 206C, where it is removed from the assembly 104. As the drying gas 116A travels within the first portion of the assembly 206A towards the second portion of the assembly 206B, the drying gas 116A passes through a first filter 220A which filters the drying gas 116A entering the assembly 104 in addition to any filtering taking place within the spray dryer device 102 between the drying gas source 116 and the drying gas inlet 212. In certain embodiments, the first filter 220A is a 0.2 micron filter having a minimum BFE (bacterial filter efficiency) of 106. The filter 220A further helps to ensure the cleanliness of the flow of drying gas 116A.
  • In an embodiment, during primary drying, the flow of drying gas BFE received by the spray drier assembly BFE may possess a temperature between about 50° C. and about 150° C. and a flow rate of between about 15 CFM to about 35 CFM. The flow of aerosolizing gas 116A can possess a flow rate of between about 5 L/min and about 20 L/min and a temperature between about 15° C. to about 30° C. (e.g., 24° C.). The flow of liquid sample 112A may possess a flow rate of between about 3 ml/min to about 20 ml/min. As the plasma is dried, the flow of the aerosolizing gas 114A, the flow of drying gas 116C, or both may direct the flow of the dried sample 232 through at least a portion of the spray dryer assembly 104 (e.g., the drying chamber, the collection chamber or both).
  • In an embodiment, the assembly 104 may further include a spray drying head 104A, a drying chamber 104B, and a collection chamber 104C in fluid communication with one another. The spray drying head 104A may be mounted to the frame 202 and positioned within the first transition zone 210A. So positioned, the spray drying head 104A is also positioned within the flow of drying gas 116A traveling from the first portion of the assembly 206A to the second portion of the assembly 206B. The spray drying head 104A may be further adapted to receive the flow of plasma 112A and the flow of aerosolizing gas 114A through respective feed lines 214, 216 and output aerosolized plasma 230 to the drying chamber 104B.
  • In further embodiments, the drying chamber 104B and collection chamber 104C may be positioned within the second and third portions of the assembly 206B, 206C, respectively. The drying chamber 1048 inflates under the pressure of the flow of drying gas 116A and provides space for the aerosolized blood plasma 230 and the flow of drying gas 116A to contact one another. Within the drying chamber 104B, moisture is transferred from the aerosolized blood plasma 230 to the drying gas 116A, where the drying gas 116A becomes humid drying gas 234. The aerosolized flow of blood plasma 230 and the flow of drying gas 116A are further separated, within the drying chamber 104B, into dried plasma 232 and humid drying gas 234. In certain embodiments, the dried plasma 232 may possess a mean diameter of less than or equal to 25 μm.
  • The humid drying gas 234 and dried plasma 232 are further drawn into the collection chamber 104C through an inlet port 222A of the collection chamber 104C, positioned within the second transition zone 210B, connecting the collection chamber 104C and the drying chamber 104B. The collection chamber 104 includes a second filter 220B which allows through-passage of the humid drying gas 234 and inhibits through-passage of the dried plasma 232. As a result, the humid drying gas 234 passing through the filter 220B is separated from the dried plasma 232 and exhausted from the collection bag 104C through an exhaust port 222B of the collection chamber 104C that forms the second end 208B of the body 204. For example, a vacuum source (e.g., a vacuum pump) may be in fluid communication with the exhaust port 222B of the collection chamber 104C to urge the humid drying gas 234 through exhaust port b. Concurrently, the dried plasma 232 is retained in a reservoir 228 of the collection chamber 104C. The collection chamber 104C is subsequently hermetically sealed at about the inlet and exhaust ports 222A, 222B, and detached (e.g., cut) from the spray dryer assembly 104, allowing the collection chamber 104C to subsequently function as a storage vessel for the dried plasma 232 until use.
  • With reference to FIG. 3, the collection chamber 104C further includes a plurality of one- way valves 702A, 702B positioned at about the inlet port 222A and the exhaust port 222B, respectively. The one-way valve 702A may function to permit gas flow from the drying chamber 104B to the collection chamber 104C and inhibit gas flow from the collection chamber 104C to the drying chamber 104B. The one-way valve 702B may function to permit gas flow from the collection chamber 104C while inhibiting gas flow into the collection chamber 104C via the exhaust port 222B.
  • The collection chamber 104C may be further configured for use in rehydrating the dried plasma 232. For example, the collection chamber 104C may include a rehydration port 224, a plurality of spike ports 226, and a vent port 228. The rehydration port 224 may be used to communicate with a source of rehydration solution, allowing the rehydration solution to come in contact with the dried plasma 232 within the collection chamber 104C to form reconstituted plasma. The reconstituted plasma may be subsequently drawn from the collection chamber 104C through the spike ports 226.
  • The temperature of the collection chamber 104C may be regulated by measuring the temperature of the humid exhaust gas 234A as it exits the collection chamber 104C. One or more of the flow rate of the drying gas 116A, and the temperature of the drying gas 116A may be adjusted, based upon the temperature of the humid exhaust gas 234A, to maintain the collection chamber 104C at temperatures less than about 70° C. and preferably at about 50° C. to about 60° C. or about 55° C.
  • Control of the Spray Drying Process via Control of the Exhaust Temperature
  • Spray Drying System
  • The purpose of this section is to describe the design of the process flow and software for the Velico Spray Dry Plasma (SpDP) system and derive the software-specific requirements from higher-level requirements. This description is exemplary only and those of ordinary skill in the art will be able to develop variations and improvements based on the teachings of this application.
  • Architecture
  • Hardware Description: See, FIG. 5. The Spray-Dry Plasma (SpDP) control system runs on a small computer capable of running, for example, the open-source Linux operating system. This computer is connected to a LabJack U6 I/O controller via USB. This computer is connected via Ethernet to all external systems including a computer used to provide the web-based user interface.
  • Automation Software: The automation software is responsible for controlling the spray-dry process. The master state machine controls the sequence of operations required to conduct the drying process. There are individual controllers for the subsystems that require active feedback to achieve specific set points during the drying process.
  • The update cycle runs at approximately 10 Hz. During each update the values of the sensors are read, the control system computations are executed, and the new output values are written out. Data is logged to an internal database which may be accessed by the blood center computer systems and/or the web user interface described next.
  • User Interface Software: The user interface to the spray-dry instrument is implemented as web pages served by the automation computer. Any computer running a web browser may be used to access the user interface pages provided the user authentication is successful.
  • Automation Software Design
  • Main State Machine, see FIG. 6
  • Off/On—These states do not have any software associated with them.
  • Self-Test—In the self-test state the operating system is booted up and diagnostic tests are performed to ensure that the hardware is functioning correctly.
  • Ready—In this state the system is ready to dry and waiting for the disposable to be loaded.
  • Disposable Integrity Test—Once the disposable (the disposable comprises a self-contained spray dry chamber and product collection bag) has been loaded the system conducts an integrity test to ensure that the disposable is loaded properly and not leaking.
  • Drying, see, FIG. 7
  • Startup—In this state the air dryers are started with the drains open and the aerosol controller is started.
  • Starting Dryers—This state waits for a specific period of time to allow the aerosol compressed air to come up to pressure and the dryers to start operating. Once this period of time has elapsed:
  • The dryer drains are closed The drying gas flow rates is set for drying and the controller is enabled The heater controller set point is set for drying and the controller is enabled. The aerosol gas flow rate is set for drying.
  • Starting Drying Gas—In this state the drying gas is coming up to speed and temperature. The criteria for moving on to the next state are:
  • Drying gas temperature more than 85% of the target temperature for drying. Drying gas flow rate more than 85% of the target flow rate for drying. Start-up Exhaust temperature observed by T5 more than 65° C.
  • Once these conditions are satisfied, the peristaltic pump flow rate is set to half of the value which will be used for drying. Fluid Half-Speed—In this state the fluid is running at half the rate which will be used for drying. To move onto the next state the drying gas temperature must be as the target set point for drying.
  • Fluid Full-Speed—This is the primary state for drying the full unit of plasma. The scale value is monitored and when the full unit has been processed the state moves forward to the Finished state.
  • Finished—This state is entered upon successful completion of drying the full unit of plasma.
  • Aborted—This state is entered if any of the consistency checks performed during the drying process fail and the unit must be discarded.
  • Stopping—This state turns off the drying equipment as follows:
      • Air dryers are powered off
      • Drying gas pump is stopped
      • Heater power is turned off
  • The peristaltic pump is switched to reverse to back the plasma away from the spray nozzle and prevent dripping of liquid plasma into the dry product.
  • Stopped—This state completes the shut-down process by turning off the peristaltic pump and shutting down its controller.
  • Controllers—All of the controllers except the peristaltic pump controller use a PID
  • (Proportional/Integral/Derivative) control loop with the gains chosen to provide the performance required by the spray-dry system. The peristaltic pump has its own controller so the set point is just transformed to an analog set point value.
  • Aerosol—The aerosol controller maintains a flow set point by monitoring the flow sensor F1 and controlling the PWM duty cycle to the variable valve V2. The aerosol controller also maintains pressure in the pneumatic reservoir by controlling the aerosol gas pump and the soft-start valve V5. A feed-forward term is used to compensate for the changing pressure observed at P1, which goes up quickly when the aerosol gas pump is running and drops slowly when the aerosol gas pump is off.
  • Drying Gas—The drying gas controller maintains a flow set point by monitoring the flow sensor F2 and controlling the analog voltage to the drying gas pump motor controller.
  • Heater—The heater controller maintains a temperature set point for the drying gas by monitoring the temperature sensor T5 and modulating the power to the heater. The heater power is modulated with a duty cycle of approximately 1 Hz to provide reasonably good time resolution with the heater power switching on zero crossings at the 60 Hz (or 50 Hz) power line frequency.
  • Peristaltic Pump—The peristaltic pump controller transforms the commanded flow rate to an analog voltage command for the pump controller. There are also two digital lines for forward/reverse and brake. The forward/reverse line is controlled based on the sign of the flow rate. A negative flow rate can be used to back up the pump and prevent liquid from dripping out of the spray nozzle at the end of the drying cycle. The brake is set when the flow rate is zero to completely stop the pump.
  • Exhaust Gas—The exhaust gas controller maintains a set exhaust temperature by monitoring the temperature sensor T6 and adjusting the set point of the drying gas flow controller. A higher flow rate results in a higher exhaust temperature. The flow rate is controlled rather than the drying gas temperature because it is much quicker to respond as necessary to maintain the exhaust gas temperature set point.
  • The error value used by this controller is the difference between the exhaust gas temperature observed at T6 and the set point (° C.). The controller determines an offset to apply to the drying gas flow rate set point. The gains used by the controller are:
      • Proportional gain: −40.0
      • Integral gain: −0.1
      • Derivative gain: 0.0 (the derivative gain is not used)
  • The output of this controller is limited to the range −150.0L/min to +150.0 L/min adjustment to the commanded flow rate. The error integrator is saturated at a value that would maximize the controller output. This prevents the integrator from winding up significantly when the controller is unable to achieve the set point.
  • Data Logging—The following data is logged to a database on the automation computer:
      • Date and time the spray-dry process is initiated
      • Any data configured for capture by the blood center, possibly including any or all of the following:
        • Operator ID
        • Donation ID
        • Disposable ID
        • Moisture barrier bag ID
        • All sensor values at 1 Hz during the drying process
        • Success or failure of the drying process
  • User Interface Software Design
  • Web Pages and Data Flow—The user interface web pages are generated by cgi programs written in C++. Communication between these user interface web pages and the automation software is accomplished using POSIX queues. The automation software creates the queues and publishes the data while the system is running to the monitor queues. It also listens for input from the user interface on the command queues.
  • Automated Drying—The automated drying user interface contains the minimal controls and status information required by an operator to conduct the drying process.
  • Diagnostics—The diagnostics user interface shows all of the sensor values and controller set points in real time while the system is operating. This facilitates process development and diagnosis of hardware issues.
  • Data Access—The data access user interface allows downloading of data stored in the automation computer database.
  • Drying Gas Control, See, FIG. 8
  • The drying gas control system takes air from outside environment and conditions it for use as drying gas. The air is filtered, dehumidified and heated as it is pumped at a controlled flow rate through the system. P.S.=pressure sensor; T.S.=temperature sensor; N.O.=valve. The specific components in this flow path are:
      • P3 Ambient pressure (absolute)
      • HEPA: High-efficiency filter
      • P4 Pressure after the filter, used to compute the pressure drop across the filter and determine when it must be changed.
      • T1, H1: relative humidity and temperature of the incoming air flow
      • AD1: dehumidifier to remove moisture from the incoming air flow
      • F2: This flow sensor is used to control the pump speed for a fixed drying gas flow rate
      • T2: Temperature before the pump
      • P5: Pressure before the pump: this is used to determine the pressure drop across the dehumidifier and the pressure increase by the pump
      • P6: Pressure after the pump
      • T3: Temperature after the pump. There is a significant temperature increase due to compression by the pump.
      • HEPA: this 0.2 um filter removes any particulate that may have been generated by the pump
      • P10: Pressure after first HEPA filter.
      • HEPA: this 0.2 um filter provides additional filtration of the drying gas. There should be no particulate from the pump at this point because it should be removed by the first HEPA filter after the pump.
      • V3: This valve can block the drying gas flow path at the end of the drying process to facilitate removal of air from the drying chamber disposable
      • P7: This is the pressure presented to the head of the drying disposable. This value is used for consistency checking to ensure proper performance of the disposable during the drying process.
      • T4: Temperature prior to entering the heater
      • Heater: This heater brings the drying gas up to the correct temperature.
      • T5: This temperature sensor is used to control the heater and achieve the correct drying gas temperature
  • The spray-dry process requires consistent flow and temperature of the drying gas so both of these attributes are actively controlled. The drying gas flow rate is measured by the flow sensor F2 and a feedback loop controls the motor speed to achieve the correct drying gas flow rate. The temperature is measured by the temperature sensor T5 and a feedback loop controls the heater power to achieve the correct drying gas temperature.
  • Exhaust Gas Management, See, FIG. 9
  • The drying gas leaving the disposable contains all of the moisture that was evaporated from the plasma. The exhaust gas management system incorporates a second dehumidifier to remove this moisture. The exhaust gas management system also incorporates a back-up filter and instrumentation to monitor the performance of the drying process. N.C.=control valves; RSH=humidity sensor; F.S.=flow sensor. The specific components in this flow path are:
      • T6: Temperature of the drying gas as it leaves the disposable. This value is used to monitor the performance of the drying process.
      • P8: Pressure leaving the disposable: this is used to compute the pressure drop across the final HEPA filter to determine when it needs to be replaced.
      • Venturi vacuum: once the drying process is complete, the valve N.O. is closed and then the vacuum pump may be used to evacuate the air from the disposable.
      • V4: This valve is used to close off the disposable from the system exhaust as noted earlier.
      • V5, V6: These valves control access from the flow path to the venture vacuum pump. These valves are closed during normal operation and disposable integrity testing, and are opened to facilitated evactuation of the air from the drying chamber and the collection filter bag.
      • ULPA: This 0.1 um filter ensures that any biohazard material that escapes from a failed disposable collection filter cannot leave the system.
      • P9: This is the final pressure, used to compute the pressure drop across the HEPA filter and also the pressure drop across the final air dryer.
      • AD2: This dehumidifier removes the water which was evaporated from the plasma.
      • H4, T7: These sensors monitor the final humidity and temperature of the exhaust gas prior to release from the system.
      • F3: This exhaust flow sensor is used to cross-check with the drying gas inlet and aerosol gas flow sensors
  • Process development experiments conducted by the inventors have shown that the temperature of the drying gas as a passes through the collection bag is a key parameter with respect to preservation of the coagulation factor proteins. The system design addresses this issue by creating an outer control loop to maintain the temperature of the drying gas as it leaves the collection bag. The control loop feeds back this temperature and increases the drying gas flow to bring the final temperature up or reduces the flow to bring the final temperature down.
  • Mechanical, See, FIGS. 10 and 11
  • Operator Interface—The spray-dry unit has mechanical features to facilitate hanging the incoming plasma unit, mounting the drying disposable, loading and clamping the plasma tube in the peristaltic pump, and removing the disposable components after the drying process is completed.
  • Disposable Mounting and Constraint—The disposable drying chamber has connections at the top for the plasma feed, aerosol gas feed, and drying gas feed. It has a connection at the bottom for the exhaust gas. The system constrains the disposable so it may inflate only to the volume required by the drying process. This minimizes the mechanical strength required of the disposable, allowing the use of a relatively thin material which may soften somewhat during the drying process without losing its integrity and leaking.
  • Heater Connections—The heater assembly is comprised primarily of stainless steel for strength and heat resistance. This structure has a relatively large thermal mass so it takes some time to come up to operating temperature or cool back down to the temperature of the ambient environment. This heat-up and cool-down time is decoupled from the processing cycle by leaving the heater assembly hot while the disposable is changed between cycles. There is a thermal break between the heater and the disposable interface so the operator is not exposed to hot surfaces that are unsafe to touch between cycles.
  • Drying Instrument Filters—The filters incorporated into the drying instrument provide an additional level of protection for the plasma being processed.
  • The air used for drying gas is cleaned before it enters the disposable. The drying disposable incorporates its own additional filtering. The region of the instrument where the disposable docking is performed is additionally protected by filtered laminar air flow to significantly reduce any bio-burden that might be introduced while docking the disposable. Service Interface—The system is designed to facilitate routine maintenance by trained personnel at the customer facility.
  • Filters—The HEPA filters which are incorporated into the device are designed to be changed by trained service personnel as necessary. The drying system monitors pressure drops across the filters and reports to the operator when a filter needs to be changed.
  • SUMMARY
  • The entire teachings of the all applications, patents and references cited herein are incorporated herein by reference. Specifically, U.S. Pat. Nos., 7,993,310, 8,469,202, 8,533,971, 8,407,912, 8,595,950, 8,601,712, 8,533,972, 8,434,242, U.S. Patent Publication Nos. 2010/0108183, 2011/0142885, 2013/0000774, 2013/0126101, 2014/0083627, 2014/0083628, 2014/0088768, and U.S. patent application Ser. No. 14/670,127 are incorporated herein by reference.
  • Ranges of values include all values within the range not specifically mentioned. For example, a range of “20% or greater” includes all values from 20% to 100% including 35%, 41.6%, 67.009%, etc., even though those values are not specifically mentioned.
  • The term “about,” such as “about 20%” or “about pH 7.6,” shall mean ±1%, ±2%, ±5%, or ±10% of the value given.
  • EXEMPLIFICATION Example 1
  • Plasma Protein Activity Correlated with Drying Gas Exhaust Temperature
  • We found that the most important parameter with respect to protein viability in dried plasma was the drying gas exhaust temperature. If dried plasma is exposed to an exhaust temperature higher than 60° C., even briefly, plasma protein activity degrades. Please note, during the drying process the surface of the wet plasma droplets is exposed to 125° C. but the droplet remains cool due to the evaporation process. A significant improvement in process consistency was achieved by actively controlling the exhaust temperature by varying the speed of the drying gas pump and, thus, the flow rate of the drying gas through the spray drying apparatus.
  • When bleeding occurs, the body causes coagulation factors, such as Fibrinogen and/or Factor V, to combine and produce a clot which stops bleeding. Insufficient protein activity may impair clot formation, resulting in excessive bleeding. Accordingly, it is desirable that the protein activity of dried plasma is relatively unchanged as compared to its liquid state. When these blood proteins are damaged, such as by exposure to elevated temperature during plasma drying, measured protein activity is reduced.
  • Residual moisture and protein activity generally decreased as exhaust temperature increased. Our data indicate that Fibrinogen and Factor V are the elements most sensitive to temperature, with activity reductions of 40% and 19%, respectively, when the exhaust temperature was 70° C. FIG. 12 represents the ratio of the protein activity of dried plasma to the protein activity of the liquid plasma and may vary between 1.0 to 0. High values of normalized protein activity, approaching 1.0, indicate that the proteins within the dried plasma are relatively undamaged, as compared to the liquid plasma. In contrast, low values of normalized protein activity, approaching 0, indicate that the proteins within the dried plasma are relatively damaged, as compared to the liquid plasma.
  • With exhaust temperatures in the range of 55-60° C., all protein activity measurements were within 15% of native plasma, with moisture content at about 4.5%. FIG. 12 plots the normalized protein activity as a function of temperature within the range between 55° C. to 70° C. As noted below, collection chamber temperature correlates with collection bag exhaust temperature and is about 3° C. higher than the exhaust temperature. Thus, collection bag temperature and collection bag exhaust temperature are proxies for each other. FIG. 12 shows that protein activity increases for each of Fibrinogen and Factor V as the collection chamber temperature decreases from about 70° C. to about 55° C. For example, the normalized activity of Fibrinogen increases from about 0.60 to about 0.925, while the normalized activity of Factor V increases from about 0.83 to about 0.97 over this range. Accordingly, embodiments of the drying processes discussed herein should be performed such that the temperature of the collection chamber is about 55° C.
  • Example 2
  • Controlling Exhaust Gas Temperature Maintains Consistent Spray Drier Temperature
  • In this study, 220 mL of plasma was spray dried on the Velico Medical Alpha 1 spray drier apparatus using the configuration show in FIG. 8. Input parameters were as follows: Plasma fluid flow rate: 10 mL/minute; Aerosol gas flow rate: 20 L/minute; Drying gas initial temperature: 125° C.; Drying gas flow rate 550-750 L/minute; Drying gas exhaust temperature: 52° C. The exhaust gas temperature was maintained at about 52° C. by varying the drying gas flow rate.
  • To map the gradient in the spray drier during spray drying, temperature probes were placed at the drying head, the inlet of the collection filter bag and at the exhaust of the collection filter bag. In FIG. 9, temperature sensor T5 measures the inlet drying gas temperature; temperature sensor T8 measures the inlet collection filter bag temperature, temperature sensor T6 measures the exhaust gas temperature as it leaves the collection filter bag. Pressure sensor P7 measures the pressure generated during the spray drying process. The temperature difference between the T5 and T8 temperature sensors shows the temperature drop caused by the drying process and released of moisture from the aerosolized plasma droplets.
  • FIGS. 13, 14 and 15 show the results of three separate experiments. The results show that by maintaining the exhaust gas temperature as a constant 52° C., the temperature at the drying gas inlet and at the inlet of the collection filter bag were also constant.
  • Example 3
  • Plasma Powder Moisture Correlated with Exhaust Gas Temperature
  • The correlation between spray drier exhaust gas temperature and moisture content of the spray dried plasma was determined. Spray dryer parameters used were
      • Drying Gas Flow Rate: 600-850 L/min
      • Drying Gas Initial Temperature: 125-135° C.
      • Drying Gas Exhaust Temperature: 30-70° C.
      • Fluid Flow Rate: 8-10 ml/min
      • Velico Medical Alpha 1 Spray Dryer
  • Exhaust gas temperature was controlled at various temperatures from 30° C. to 70° C. Residual moisture in the dried plasma was measured by the Karl Fisher method for dried plasma collected in the collection filter. FIG. 16 shows the residual moisture content of the dried plasma ranged from about 15% when the exhaust temperature was maintained at about 30° C. to about 4.0% when the exhaust temperature was maintained at about 70° C. As indicated above, when the spray drier was operated to keep the exhaust gas temperature from about 55-60° C., the plasma protein activity was measured to be within 15% of the native protein. Likewise, preferred residual moisture content of from about 4% to about 6% was obtained when the exhaust gas temperature was maintained from about 60° C. to about 52° C., respectively. Thus, the present invention contemplates operating the spray drier apparatus so that the exhaust gas temperature ranges from about 52° C. to about 60° C. with the preferred exhaust gas temperature being from 54° C. to 58° C. or about 55° C.
  • When taken together, the results of Examples 1, 2 and Example 3 show that maintaining the exhaust gas temperature at a predetermined temperature (temperature range) results in a suitably dried plasma powder with acceptable plasma protein activity recovery.

Claims (10)

We Claim:
1. A method of controlling the moisture content of a spray dried plasma, the method comprising:
a) providing: i) plasma, and ii) a spray drying apparatus, comprising, a mechanism for aerosolizing the plasma, a mechanism to deliver drying gas at a controlled rate, a drying chamber, a collection chamber and a sensor for measuring exhaust gas temperature as it emerges from the drying process;
b) operating the spray drying apparatus to produce a moisture controlled spray dried plasma, said operation comprising controlling the moisture content of the spray dried plasma collected in the collection chamber by measuring the exhaust gas temperature with the sensor for measuring exhaust gas temperature and adjusting the flow of the drying gas based on the exhaust gas temperature wherein the flow of the drying gas is increased to increase the exhaust gas temperature and decrease the moisture content of the spray dried plasma; and the drying gas flow is decreased to decrease the exhaust gas temperature and increase the moisture content of the spray dried plasma, thereby producing a moisture controlled spray dried plasma, wherein the moisture content of the moisture controlled spray dried plasma is approximately 4 w/w % to approximately 10 w/w %.
2. The method of claim 1, wherein said moisture content of the moisture controlled spray dried plasma is approximately 4 w/w % to approximately 8 w/w %.
3. The method of claim 1, wherein said exhaust gas temperature is maintained at a set point in the range of from approximately 45° C. to approximately 65° C.
4. The method of claim 1, wherein said exhaust gas temperature is maintained at a set point in the range of from approximately 50° C. to approximately 60° C.
5. The method of claim 1, wherein said exhaust gas temperature is maintained at a set point of approximately 55° C.
6. The method of claim 1, wherein said drying gas has a temperature of about 100° C.-150° C. when it starts to mix with the aerosolized plasma.
7. The method of claim 1, wherein said drying gas flow is maintained at approximately 500 L/min to approximately 1000 L/min during the process for producing the moisture controlled spray dried plasma.
8. The method of claim 1, wherein said drying process is controlled by a computer.
9. The method of claim 1, wherein the flow rate of the drying gas flow rate and percent moisture of the moisture controlled spry dried plasma is based on previously collected data.
10. The method of claim 1, wherein said plasma is whole blood (WB) plasma or citrate phosphate dextrose (CPD) plasma.
US14/858,517 2014-09-19 2015-09-18 Process control methods for obtaining and maintaining a desired moisture content of spray dried plasma Abandoned US20160084572A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/858,517 US20160084572A1 (en) 2014-09-19 2015-09-18 Process control methods for obtaining and maintaining a desired moisture content of spray dried plasma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462052689P 2014-09-19 2014-09-19
US14/858,517 US20160084572A1 (en) 2014-09-19 2015-09-18 Process control methods for obtaining and maintaining a desired moisture content of spray dried plasma

Publications (1)

Publication Number Publication Date
US20160084572A1 true US20160084572A1 (en) 2016-03-24

Family

ID=55524748

Family Applications (6)

Application Number Title Priority Date Filing Date
US14/670,127 Active US9561184B2 (en) 2014-09-19 2015-03-26 Methods and systems for multi-stage drying of plasma
US14/858,517 Abandoned US20160084572A1 (en) 2014-09-19 2015-09-18 Process control methods for obtaining and maintaining a desired moisture content of spray dried plasma
US14/858,539 Active US9545379B2 (en) 2014-09-19 2015-09-18 Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US15/383,201 Active 2037-10-05 US11052045B2 (en) 2014-09-19 2016-12-19 Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US17/337,306 Active US11806431B2 (en) 2014-09-19 2021-06-02 Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US17/508,904 Pending US20220040110A1 (en) 2014-09-19 2021-10-22 Formulations and Methods for Contemporaneous Stabilization of Active Proteins During Spray Drying and Storage

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/670,127 Active US9561184B2 (en) 2014-09-19 2015-03-26 Methods and systems for multi-stage drying of plasma

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/858,539 Active US9545379B2 (en) 2014-09-19 2015-09-18 Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US15/383,201 Active 2037-10-05 US11052045B2 (en) 2014-09-19 2016-12-19 Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US17/337,306 Active US11806431B2 (en) 2014-09-19 2021-06-02 Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US17/508,904 Pending US20220040110A1 (en) 2014-09-19 2021-10-22 Formulations and Methods for Contemporaneous Stabilization of Active Proteins During Spray Drying and Storage

Country Status (1)

Country Link
US (6) US9561184B2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017177104A1 (en) 2016-04-07 2017-10-12 Velico Medical, Inc. Reconstitution solution for spray-dried plasma
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US10843100B2 (en) 2010-10-29 2020-11-24 Velico Medical, Inc. Spray drier assembly for automated spray drying
US11052045B2 (en) 2014-09-19 2021-07-06 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11619445B2 (en) 2017-08-31 2023-04-04 Capsugel Belgium Nv Single-use spray drying components and methods of using the same
US11639825B2 (en) * 2017-06-15 2023-05-02 Pegaso Industries S.P.A. Process for drying polymeric granular material and system operating according to said process
US11841189B1 (en) 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product
US11998861B2 (en) 2022-09-15 2024-06-04 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142885A1 (en) * 2009-09-16 2011-06-16 Velico Medical, Inc. Spray-dried human plasma
US20210290835A1 (en) * 2016-08-05 2021-09-23 Jay Yadav Plasma banking to mitigate aging
EP3589259A4 (en) 2017-03-03 2021-01-06 Rich Technologies Holding Company, LLC Device for preserving blood products and cellular cultures in a gas medium under pressure
EP3887404A4 (en) 2018-11-30 2022-11-02 Cellphire, Inc. Platelets loaded with anti-cancer agents
EP3886879A4 (en) 2018-11-30 2022-12-07 Cellphire Inc. Platelets as delivery agents
SG11202112054WA (en) 2019-05-03 2021-11-29 Cellphire Inc Materials and methods for producing blood products
BR112022002892A2 (en) 2019-08-16 2022-05-24 Cellphire Inc Thrombosomes as an antiplatelet agent reversal agent
WO2021046409A1 (en) * 2019-09-05 2021-03-11 Cellphire, Inc. Materials and methods for blood plasma preparations
WO2021158622A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets
CN114504834B (en) * 2022-02-24 2023-03-07 华夏生生药业(北京)有限公司 Calcium gluconate solution purification equipment and process thereof
US20240091665A1 (en) 2022-09-15 2024-03-21 Velico Medical, Inc. Alignment of A Disposable For A Spray Drying Plasma System
WO2024059770A1 (en) 2022-09-15 2024-03-21 Velico Medical, Inc. Rapid spray drying system
US20240091155A1 (en) 2022-09-15 2024-03-21 Velico Medical, Inc. Pretreatment Of Plasma For Spray Drying And Storage
US20240091156A1 (en) * 2022-09-15 2024-03-21 Velico Medical, Inc. Methods For Making Spray Dried Plasma
WO2024059771A1 (en) 2022-09-15 2024-03-21 Velico Medical, Inc. Two-phase delivery of plasma
WO2024059767A1 (en) 2022-09-15 2024-03-21 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system
WO2024059765A1 (en) 2022-09-15 2024-03-21 Velico Medical, Inc. Baffle plate used in a disposable for a spray drying system
US20240123367A1 (en) 2022-09-15 2024-04-18 Velico Medical, Inc. Nozzle For A Disposable For Use With Spray Drying System
US20240131062A1 (en) 2022-09-15 2024-04-25 Velico Medical, Inc. Spray Drying Process That Reduces Pathogens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6085443A (en) * 1999-09-03 2000-07-11 Pioneer Hi-Bred International, Inc. Apparatus and method for drying relatively small lots of products

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2411152A (en) 1941-05-02 1946-11-19 Theodore R Folsom Method for freezing and drying liquids and semisolids
US2528476A (en) 1942-03-20 1950-10-31 Thomas Lipton Inc Method and apparatus for dehydration
GB573500A (en) 1945-01-30 1945-11-23 Kuno Moeller Method for improving foods
US2575175A (en) * 1949-08-16 1951-11-13 Kronisch Eugene Process of making pharmaceutical preparations
FR1205833A (en) 1957-05-17 1960-02-04 Birs Beteiligungs Und Verwaltu Process for evaporating solutions and suspensions, apparatus for its implementation, products obtained and their applications
US3228838A (en) 1959-04-23 1966-01-11 Union Carbide Corp Preservation of biological substances
NL274202A (en) 1961-02-06
CH404552A (en) 1961-02-06 1965-12-15 Birs Beteiligungs Und Verwaltu Device for feeding material to a drying tower
US3449124A (en) 1964-11-13 1969-06-10 Isolated Beef Protein Suppleme Meat emulsion and method of preparing same
CH461034A (en) 1966-06-27 1968-08-15 Werding Wienfried Transfusion device
JPS4924943B1 (en) 1970-06-01 1974-06-26
US3644128A (en) 1970-12-28 1972-02-22 Stuart Lipner Method of preparing comminuted meat products
US3654705A (en) 1971-01-11 1972-04-11 Combustion Power Fluidized bed vapor compression drying apparatus and method
JPS5245301B2 (en) 1973-08-07 1977-11-15
JPS525910B2 (en) 1973-08-11 1977-02-17
JPS525910A (en) 1975-07-02 1977-01-18 Shibaura Eng Works Ltd Method of executing foundation work for poor subsoil
JPS5245301U (en) 1975-09-27 1977-03-31
CH622683A5 (en) 1976-04-14 1981-04-30 Phylaxia Oltoanyag Es Tapszert Process and apparatus for the production of soluble blood powder, and use of this blood powder for the production of food and feed additives
JPS6015B2 (en) 1977-07-16 1985-01-05 株式会社新潟鐵工所 Method for producing sterilized blood powder that is water-soluble and thermocoagulable
NZ188155A (en) 1977-08-29 1981-12-15 Henningsen Foods Air distributor plate for spray drier
US4187617A (en) 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
JPS5611903A (en) 1979-06-11 1981-02-05 Chisso Corp Preparation of powdery pectin
US4251510A (en) 1979-08-15 1981-02-17 Cutter Laboratories, Inc. Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4378346A (en) 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
JPS6040790B2 (en) 1980-03-21 1985-09-12 ヤマト科学株式会社 Basic equipment for multipurpose powder processing
JPS5935631B2 (en) 1980-07-24 1984-08-29 テルモ株式会社 Body fluid “filtration” device
DE3106073A1 (en) 1981-02-19 1982-08-19 Boehringer Mannheim Gmbh, 6800 Mannheim METHOD FOR PRODUCING STERILE PREPARATIONS OF HIGH VISCOSITY SOLUTIONS AND SUBSTANCES
CA1160593A (en) 1981-04-14 1984-01-17 Hydro-Quebec Spray drying with a plasma of superheated steam
US4380491A (en) 1981-08-26 1983-04-19 Combustion Engineering, Inc. Spray nozzle assembly for spray dryer
CA1182411A (en) 1982-03-09 1985-02-12 Mitko S. Popov Method for immobilization of glucose-isomeraze active microbial cells
JPS59197256A (en) 1983-04-25 1984-11-08 テルモ株式会社 Medical bag and production thereof
JPS60126433U (en) 1984-02-06 1985-08-26 エスエス製薬株式会社 cyclone receiver
DE3584188D1 (en) 1984-05-11 1991-10-31 Terumo Corp METHOD FOR PRODUCING A SYNTETIC RESIN CONTAINER.
US4678566A (en) 1984-07-20 1987-07-07 Terumo Kabushiki Kaisha Apparatus for separating proteins from blood plasma
JPS6145773A (en) 1984-08-07 1986-03-05 テルモ株式会社 Material and apparatus for purifying body fluids
DE3564078D1 (en) 1984-11-09 1988-09-08 Terumo Corp Flat permeable membrane and method for manufacture thereof
DE3666697D1 (en) 1985-02-08 1989-12-07 Terumo Corp Method fo plasma-initiated polymerization
DE3507278A1 (en) 1985-03-01 1986-09-04 Robert Bosch Gmbh, 7000 Stuttgart Electrohydraulic control device
JPS62262705A (en) 1986-05-07 1987-11-14 Agency Of Ind Science & Technol Hydrophilic porous membrane, its production and serum separator using said membrane
EP0250939B1 (en) 1986-06-12 1992-04-01 Hans Joachim Dipl.-Ing. Titus Suction filter drier
JPS6336419U (en) 1986-08-21 1988-03-09
KR940002379B1 (en) 1987-01-20 1994-03-24 데루모 가부시끼가이샤 Porous polypropylene membrane and process for its production
JPH0824801B2 (en) 1987-03-05 1996-03-13 ティーディーケイ株式会社 Method and device for removing powder
JPS6411618A (en) 1987-07-06 1989-01-17 Tdk Corp Device for recovering powders
AU611244B2 (en) 1987-12-25 1991-06-06 Terumo Kabushiki Kaisha Medical instrument
US4861632A (en) * 1988-04-19 1989-08-29 Caggiano Michael A Laminated bag
US4966699A (en) 1988-05-25 1990-10-30 Terumo Kabushiki Kaisha Hollow fiber membrane fluid processor
US5309649A (en) 1988-05-26 1994-05-10 Boehringer Mannheim Gmbh Process and container for freeze drying under sterile conditions
US5244578A (en) 1989-09-28 1993-09-14 Terumo Kabushiki Kaisha Blood plasma-separating membrane and blood plasma separator using the membrane
JP3301610B2 (en) 1989-10-17 2002-07-15 ティーディーケイ株式会社 Porous filter for spray drying
JPH0677641B2 (en) 1989-12-08 1994-10-05 ティーディーケイ株式会社 Porous filter for spray dryer
JPH0641603Y2 (en) 1990-03-08 1994-11-02 株式会社坂本技研 Spray dryer
NL9001087A (en) * 1990-05-07 1991-12-02 Harimex Ligos Bv METHOD FOR PURIFYING BLOOD PLASMA.
US5137635A (en) 1990-06-26 1992-08-11 Terumo Kabushiki Kaisha Permeable membrane excellent in biocompatibility
JP2953753B2 (en) 1990-06-28 1999-09-27 テルモ株式会社 Plasma collection device
US5096537A (en) 1990-06-28 1992-03-17 Henningsen Foods, Inc. Tower spray dryer with hot and cool air supply
FR2664982B1 (en) 1990-07-20 1994-04-29 Serbio APPARATUS FOR DETECTING CHANGE IN VISCOSITY, BY MEASURING RELATIVE SLIDING, PARTICULARLY FOR DETECTING BLOOD COAGULATION TIME.
CZ3869U1 (en) * 1990-11-07 1995-09-26 Otsuka Pharmaceutical Factory, Inc. Storage bin with plurality of chambers
US5145706A (en) 1991-03-28 1992-09-08 Taiyo Kagaku Co., Ltd. Method for preparation of plasma powder and product thereof
US5257983A (en) 1991-04-12 1993-11-02 Cryopharm Corporation Blood bag for lyophilization
AR244098A1 (en) 1991-04-12 1993-10-29 Daniel Alberto Mayolo A transportable industrial plant for drying different liquids into a powder.
JP3219828B2 (en) 1992-03-05 2001-10-15 ティーディーケイ株式会社 Method of discharging residual gas from spray drying device and method of removing it
EP0642301B1 (en) 1992-05-29 2003-03-12 The University Of North Carolina At Chapel Hill Pharmaceutically acceptable fixed-dried human blood platelets
US5529821A (en) 1992-06-29 1996-06-25 Terumo Kabushiki Kaisha Container for storing blood or blood component
EP0586268B1 (en) 1992-07-06 2000-02-23 Terumo Kabushiki Kaisha A pathogenic substance removing material and a blood filter comprising said material
US5523004A (en) 1992-12-04 1996-06-04 Terumo Kabushiki Kaisha Method for treatment of blood using a blood bag
ATE166224T1 (en) * 1993-01-22 1998-06-15 Otsuka Pharma Co Ltd STORAGE CONTAINER FOR POWDERED MEDICATIONS CONTAINING BICARBONATE AND METHOD FOR STABILIZING SUCH MEDICATIONS
IL105658A (en) 1993-05-11 1995-10-31 Ultrasonic Dryer Ltd Spray drying system
US5562919A (en) 1993-05-20 1996-10-08 American Meat Protein Corporation Dried animal plasma as a pharmaceutical excipient for compressed tablet formulation
US5575999A (en) 1993-12-03 1996-11-19 Ampc, Inc. Animal feed supplement containing co-sprayed dried plasma protein and amylase
US5372811A (en) 1993-12-03 1994-12-13 American Meat Protein Corporation Animal feed supplement containing co-spray dried plasma protein and amylase
AU680727B2 (en) 1994-02-09 1997-08-07 Kinerton Limited Process for drying a material from solution
US5522156A (en) 1994-04-26 1996-06-04 Ware; Gerald J. Drying apparatus and method
DE4441167C1 (en) 1994-11-18 1996-03-14 Fraunhofer Ges Forschung Prodn. of blood plasma as virus free dry granulate
US20030143518A1 (en) 1994-11-18 2003-07-31 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Method of drying blood plasma
US5581903A (en) 1994-11-22 1996-12-10 Botich; Leon A. Apparatus for heating purge gas and transmitting microwave energy for desiccant regeneration
US5567238A (en) 1994-12-06 1996-10-22 Coating Machinery Systems, Inc. Oscillating bed seed coating machine for particulate material
GB9607636D0 (en) 1996-04-12 1996-06-12 Pafra Ltd Storage of materials
US5647142A (en) 1996-05-13 1997-07-15 Niro A/S Apparatus and process for drying a moist material dispersed or dispersible in a stream of drying gas
US6308826B1 (en) * 1996-05-29 2001-10-30 Mallinckrodt Inc. Bulk packaging system and method for retarding caking of organic and inorganic chemical compounds
EP0904844A4 (en) 1996-06-10 2005-08-31 Nippon Telegraph & Telephone Two-fluid nozzle and device employing the same nozzle for freezing and drying liquid containing biological substances
JP3585654B2 (en) 1996-07-11 2004-11-04 株式会社パウダリングジャパン Two-stage drying spray dryer
JPH10182124A (en) 1996-12-20 1998-07-07 Kawasaki Steel Corp Treatment of slice loss of silicon substrate
US6046051A (en) 1997-06-27 2000-04-04 Hemosense, Inc. Method and device for measuring blood coagulation or lysis by viscosity changes
US6197289B1 (en) 1997-07-01 2001-03-06 Terumo Cardiovascular Systems Corporation Removal of biologically active agents
EP0896824A1 (en) 1997-08-05 1999-02-17 Octapharma Ag A universally applicable blood plasma
US20020182195A1 (en) 1997-08-05 2002-12-05 Octapharma Ag Universally applicable blood plasma
US6004576A (en) 1997-08-11 1999-12-21 Ampc, Inc. Granular plasma protein supplement with increased bio-efficacy
FR2775064B1 (en) 1998-02-16 2000-05-05 Sidel Sa METHOD FOR DRYING HOLLOW BODIES AND DEVICE FOR CARRYING OUT SAID
US6299906B1 (en) * 1998-04-09 2001-10-09 Hoffmann-La Roche Inc. Process for making submicron particles
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
JP4221637B2 (en) 1998-09-25 2009-02-12 日本薬品開発株式会社 Production method of vinegar egg powder
USD430939S (en) 1999-02-11 2000-09-12 Gore Enterprise Holdings, Inc. Lyophilization container
AR023135A1 (en) 1999-03-23 2002-09-04 American Protein Corp SUPPLEMENT OF ANIMAL PLASMA FOR WATER CROPS
US6560897B2 (en) 1999-05-03 2003-05-13 Acusphere, Inc. Spray drying apparatus and methods of use
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
AU7383200A (en) 1999-09-14 2001-04-17 Charles R. Meldrum Produce drying system utilizing multiple energy sources
US6463675B1 (en) 1999-09-29 2002-10-15 Niro A/S Process and a plant for spray drying
US6750053B1 (en) 1999-11-15 2004-06-15 I-Stat Corporation Apparatus and method for assaying coagulation in fluid samples
US6582654B1 (en) 2000-02-07 2003-06-24 Steris Inc. Fluid spray system for cleaning and sterilizing medical devices supported on a rack
AU2001234978A1 (en) 2000-02-10 2001-08-20 The Regents Of The University Of California Therapeutic platelets and methods
US20040086420A1 (en) * 2000-03-23 2004-05-06 Macphee Martin J. Methods for sterilizing serum or plasma
US6569447B2 (en) 2000-03-24 2003-05-27 Trouw Nutrition Usa, Llc Combination of plasma and hyperimmunized products for increased performance
CN1127299C (en) 2000-03-30 2003-11-12 上海杰隆生物工程股份有限公司 Process for preparing animal plasma protein powder
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
JP2002009037A (en) 2000-06-23 2002-01-11 Sony Corp Gas-spraying-system drying method and device
WO2002024169A1 (en) 2000-09-20 2002-03-28 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
US7297716B2 (en) 2000-10-23 2007-11-20 Shanbrom Technologies, Llc Enhanced production of blood components, blood cells and plasma without freezing
US6743596B1 (en) 2000-10-27 2004-06-01 Biomerieux, Inc. Method of determining global coagulability hemostatic potential
JP4299452B2 (en) 2000-11-28 2009-07-22 テルモ株式会社 Platelet collection device
GB0030929D0 (en) 2000-12-19 2001-01-31 Inverness Medical Ltd Analyte measurement
US20030103962A1 (en) 2001-10-09 2003-06-05 Campbell Joy M. Methods and compositions for modulating the immune system of animals
US20030190314A1 (en) 2001-01-30 2003-10-09 The Lauridsen Group Methods and compositions of treatment for modulating the immune system of animals
US20030099633A1 (en) 2001-10-09 2003-05-29 Campbell Joy M. Methods and compositions for treatment of immune dysfunction disorders
CA2437099A1 (en) 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for treatment of immune dysfunction disorders
EP1357943A2 (en) 2001-01-30 2003-11-05 The Lauridsen Group Incorporated Methods and compositions for modulating the immune system of animals
CN1207004C (en) 2001-04-18 2005-06-22 马建川 Freeze-dried plasma without blood group and its preparation method
FR2824754B1 (en) 2001-05-15 2004-05-28 Separex Sa PROCESS FOR OBTAINING SOLID PARTICLES FROM AT LEAST ONE WATER-SOLUBLE PRODUCT
US6526774B1 (en) 2001-08-14 2003-03-04 Shun-Tsung Lu Device for separating dry solid and liquid by cooling spray
US7011742B2 (en) 2001-09-14 2006-03-14 Zymequest, Inc. Blood product transfer system
US7204828B2 (en) 2001-09-14 2007-04-17 Zymequest, Inc. Collection needle
NL1019142C2 (en) 2001-10-08 2003-04-09 Harimex Bv Method for the preparation of animal plasma powder, method for promoting the health and growth of animals and the animal feed thus obtained.
NL1019143C2 (en) 2001-10-08 2003-04-09 Nutricia Nv Pharmaceutical product or dietary supplement and an intermediate product to be used.
US20040058309A1 (en) * 2001-10-12 2004-03-25 Junji Washizu Plasma supplement and use in liver assist systems
CA2464250C (en) 2001-10-24 2008-08-05 Frank-Christophe Lintz Kit for the preparation of a pharmaceutical composition
DE60227691D1 (en) 2001-11-01 2008-08-28 Nektar Therapeutics SPRAY DRYING PROCESS
NL1019873C2 (en) 2002-01-31 2003-08-04 Harimex Bv Method for preparing a blood plasma powder, and applications thereof.
CA2472028C (en) 2002-02-01 2010-03-30 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
DE60318938T2 (en) 2002-03-20 2009-01-22 Mannkind Corp., Valencia INHALER
US6720054B2 (en) * 2002-03-27 2004-04-13 Koslow Technologies Corporation Desiccant system including bottle and desiccant sheet
ES2234349B1 (en) 2002-04-18 2006-11-01 Servicio De Instrumentacion Hospitalaria, S.L. DEVICE FOR MEASUREMENT OF COAGULATION TIME AND PLAQUETARY ACTIVITY AND, PROCEDURE OF THE SAME.
US7179526B2 (en) 2002-08-02 2007-02-20 3M Innovative Properties Company Plasma spraying
US7074172B2 (en) 2002-08-02 2006-07-11 Zymequest, Inc. Processing bag for component separator system and method of removing separated components
US7089681B2 (en) 2002-11-26 2006-08-15 Alkermes Controlled Therapeutics, Inc. Method and apparatus for filtering and drying a product
GB0230152D0 (en) 2002-12-24 2003-02-05 Sinvent As Product
NL1022291C2 (en) 2002-12-31 2004-07-15 Carlisle Process Systems B V Method and device for the manufacture of whey powder.
US20040146565A1 (en) 2003-01-28 2004-07-29 Lauridsen Group Incorporated First lipoprotein fraction and therapeutic compositions of same
GB0305133D0 (en) 2003-03-06 2003-04-09 Sinvent As Product
US20050186183A1 (en) * 2003-12-08 2005-08-25 Deangelo Joseph Stabilized products, processes and devices for preparing same
WO2005061088A1 (en) 2003-12-22 2005-07-07 Finlay Warren H Powder formation by atmospheric spray-freeze drying
US7007406B2 (en) 2004-01-23 2006-03-07 Zhaolin Wang Powder formation by atmospheric spray-freeze drying
JP4348176B2 (en) 2003-12-25 2009-10-21 積水化学工業株式会社 Dry etching processing apparatus and processing method
EP1713441A2 (en) 2004-02-12 2006-10-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US7737214B2 (en) 2004-03-15 2010-06-15 Terumo Kabushiki Kaisha Adhesion preventive material
US7399637B2 (en) 2004-04-19 2008-07-15 Medtronic, Inc. Blood coagulation test cartridge, system, and method
EP1794524B1 (en) 2004-07-23 2012-01-18 Bayer Technology Services GmbH Sterile freezing, drying, storing, assaying and filling process (sfd-saf process) (pellet freeze-drying process for parenteral biopharmaceuticals)
WO2006028648A2 (en) * 2004-08-13 2006-03-16 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Support system for flexible lyophilization containers
US7419682B2 (en) 2004-08-30 2008-09-02 Apc, Inc. Poultry feed containing plasma
US7527805B2 (en) 2004-12-21 2009-05-05 Apc, Inc. Methods of increasing productivity in older sows while decreasing feed intake
US7776503B2 (en) 2005-03-31 2010-08-17 Ricoh Company, Ltd. Particles and manufacturing method thereof, toner and manufacturing method thereof, and developer, toner container, process cartridge, image forming method and image forming apparatus
WO2008048228A2 (en) * 2005-08-12 2008-04-24 Department Of The Army Glycine stabilized lyophilized plasma
WO2008048229A2 (en) * 2005-08-12 2008-04-24 Department Of The Army Stabilized lyophilized blood platelets
EP1945038A1 (en) 2005-09-30 2008-07-23 Niro A/S An apparatus and a process for drying high carbohydrate content liquids
JP2007216158A (en) 2006-02-17 2007-08-30 Micro Engineering Inc Substrate cleaning method and apparatus using superheated steam
US10195230B2 (en) 2006-12-14 2019-02-05 Mcneese State University Blood product from crocodylian species as a feed supplement for weanling pigs and poultry hatchlings
US8097403B2 (en) * 2006-12-14 2012-01-17 Cellphire, Inc. Freeze-dried platelets, method of making and method of use as a diagnostic agent
MX2009006806A (en) 2006-12-22 2009-08-27 Vertex Pharma Storage bag and bag furniture formed therewith.
EP1958618A1 (en) 2007-02-15 2008-08-20 Octapharma AG Method for freeze-drying with optimum reconstitution of biopolymers
US7776022B2 (en) 2007-03-19 2010-08-17 Hemcon Medical Technologies Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
US20090223080A1 (en) * 2007-03-19 2009-09-10 Hemcon Medical Technologies, Inc. Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
US8449520B2 (en) 2007-03-19 2013-05-28 HemCon Medical Technologies Inc. Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
WO2008122288A1 (en) 2007-04-10 2008-10-16 Anhydro A/S Process gas filtration
US8512697B2 (en) 2007-05-16 2013-08-20 The University Of North Carolina At Chapel Hill Delivery of micro- and nanoparticles with blood platelets
US7897112B2 (en) * 2007-06-25 2011-03-01 American Sterilizer Company Multi-chamber chemical delivery container
JP5245301B2 (en) 2007-06-28 2013-07-24 住友ベークライト株式会社 Resin composition, prepreg, laminate, and semiconductor device
WO2009049318A2 (en) * 2007-10-12 2009-04-16 Bakaltcheva Irina B Freeze-dried plasma formats for the trauma care field
US20090145783A1 (en) * 2007-12-07 2009-06-11 Nicholas Andrew Forker Apparatus and method for removing moisture from portable electronic devices
EP3130396B1 (en) 2009-03-27 2021-03-17 Bend Research, Inc. Spray-drying process
CN102292115B (en) 2009-03-30 2015-07-08 泰尔茂株式会社 Surface-treating agent, filtering material for filter, and blood treatment filter
KR100911657B1 (en) 2009-04-09 2009-08-10 (주) 액트 The dry decontamination apparatus of radioactive metallic waste and method thereof
WO2010117976A1 (en) 2009-04-09 2010-10-14 Entegrion, Inc Spray-dried blood products and methods of making same
US8383671B1 (en) 2009-06-18 2013-02-26 Abbott Cardiovascular Systems Inc. Method of treating malignant solid tumors
US20110142885A1 (en) 2009-09-16 2011-06-16 Velico Medical, Inc. Spray-dried human plasma
US8407912B2 (en) * 2010-09-16 2013-04-02 Velico Medical, Inc. Spray dried human plasma
US8450078B2 (en) 2009-12-18 2013-05-28 Entegrion, Inc. Portable coagulation monitoring device and method of assessing coagulation response
US20140083628A1 (en) 2012-09-27 2014-03-27 Velico Medical, Inc. Spray drier assembly for automated spray drying
CA2816090A1 (en) 2010-10-29 2012-05-03 Velico Medical, Inc. System and method for spray drying a liquid
US10470479B2 (en) 2013-10-04 2019-11-12 Proteus Industries, Inc. Functional protein derived from animal muscle tissue or mechanically deboned meat and method for making the same
US10569187B2 (en) 2011-02-28 2020-02-25 Gea Process Engineering A/S External mixing pressurized two-fluid nozzle and a spray drying method
JP5822488B2 (en) 2011-03-01 2015-11-24 三井化学東セロ株式会社 Blood bag packaging material and blood bag package
CN102206273A (en) * 2011-04-07 2011-10-05 安徽宝迪肉类食品有限公司 Method for extracting immunoglobulin G from pig blood
EP2578974A1 (en) * 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
WO2013116702A1 (en) * 2012-02-02 2013-08-08 Becton, Dickinson And Company Sample collection devices with blood stabilizing agents
CN104245009A (en) 2012-03-14 2014-12-24 泰尔茂株式会社 Container for testing blood and blood sampling instrument
JP2015110194A (en) 2012-03-23 2015-06-18 テルモ株式会社 Permselective membrane and method of manufacturing the same
WO2013152253A1 (en) 2012-04-05 2013-10-10 Terumo Bct, Inc. Syestem and method for collecting and treating plasma protein fractions
CN104507441B (en) 2012-07-12 2018-01-12 泰尔茂比司特公司 Mixed type blood constituent reservoir bag and the method for manufacturing this bag
US20140083627A1 (en) 2012-09-27 2014-03-27 Velico Medical, Inc. Automated spray drier
US10376809B2 (en) 2012-12-20 2019-08-13 Gea Process Engineering A/S Insert for an atomizer wheel and atomizer wheel comprising a number of such inserts
CA2897860C (en) 2013-03-11 2019-08-20 Teleflex Medical Incorporated Devices with anti-thrombogenic and anti-microbial treatment
JP6357156B2 (en) 2013-09-02 2018-07-11 テルモ株式会社 Medical device and manufacturing method thereof
US9561893B2 (en) 2013-12-05 2017-02-07 Vascular Solutions, Inc. System and method for freeze-drying and packaging
EP3088014B1 (en) 2013-12-27 2018-06-20 Terumo Kabushiki Kaisha Medical device
JP6659591B2 (en) 2014-06-09 2020-03-04 テルモ ビーシーティー、インコーポレーテッド freeze drying
WO2016036807A1 (en) 2014-09-03 2016-03-10 Entegrion, Inc. Acceleration of reconstitution of plasma powder by mixing with small beads
US9561184B2 (en) 2014-09-19 2017-02-07 Velico Medical, Inc. Methods and systems for multi-stage drying of plasma
US20160362307A1 (en) 2015-06-10 2016-12-15 Energy Water Solutions, LLC Containerized system and method for spray evaporation of water
WO2016208675A1 (en) 2015-06-23 2016-12-29 株式会社Tesホールディングス Freeze-dried platelet-rich plasma and use thereof
CN204994473U (en) 2015-08-03 2016-01-27 上海爱农机电设备有限公司 Portable superfine atomizing machine
US10806665B2 (en) 2016-01-18 2020-10-20 Teleflex Life Sciences Limited System and method for freeze-drying and packaging
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
CN108005711B (en) 2017-12-09 2020-06-19 胡楠 Underground roadway spraying dust-settling device
US10702111B2 (en) 2018-01-19 2020-07-07 Emerson Electric Co. Attachment mechanism for vacuum cleaner accessories
WO2020065413A1 (en) 2018-09-27 2020-04-02 Tapas Chatterjee Spray dryer apparatus having replaceable atomizer
JP6927182B2 (en) 2018-11-28 2021-08-25 株式会社デンソー Liquid level detector
KR20220003679A (en) 2020-07-01 2022-01-11 정하익 Seperation, crushing, dewatering, incineration, landfill, treatment, recycling equipment and method for waste, sludge, aggregate, rock
MX2023003483A (en) 2020-10-01 2023-04-14 Takeda Pharmaceuticals Co Plasma fractionation process utilizing spray-dried human plasma.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6085443A (en) * 1999-09-03 2000-07-11 Pioneer Hi-Bred International, Inc. Apparatus and method for drying relatively small lots of products

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10843100B2 (en) 2010-10-29 2020-11-24 Velico Medical, Inc. Spray drier assembly for automated spray drying
US11052045B2 (en) 2014-09-19 2021-07-06 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US11806431B2 (en) 2014-09-19 2023-11-07 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
WO2017177104A1 (en) 2016-04-07 2017-10-12 Velico Medical, Inc. Reconstitution solution for spray-dried plasma
US11639825B2 (en) * 2017-06-15 2023-05-02 Pegaso Industries S.P.A. Process for drying polymeric granular material and system operating according to said process
US11619445B2 (en) 2017-08-31 2023-04-04 Capsugel Belgium Nv Single-use spray drying components and methods of using the same
US11634257B2 (en) 2017-10-09 2023-04-25 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US11740019B2 (en) 2019-03-14 2023-08-29 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11609043B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US11609042B2 (en) * 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11747082B2 (en) 2019-03-14 2023-09-05 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11815311B2 (en) 2019-03-14 2023-11-14 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US11994343B2 (en) 2019-03-14 2024-05-28 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11841189B1 (en) 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system
US11913722B1 (en) 2022-09-15 2024-02-27 Velico Medical, Inc. Rapid spray drying system
US11913723B1 (en) 2022-09-15 2024-02-27 Velico Medical, Inc. Baffle plate used in a disposable for a spray drying system
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product
US11998861B2 (en) 2022-09-15 2024-06-04 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system

Also Published As

Publication number Publication date
US20160082044A1 (en) 2016-03-24
US20210290545A1 (en) 2021-09-23
US20160082043A1 (en) 2016-03-24
US9545379B2 (en) 2017-01-17
US20170100339A1 (en) 2017-04-13
US11052045B2 (en) 2021-07-06
US20220040110A1 (en) 2022-02-10
US11806431B2 (en) 2023-11-07
US9561184B2 (en) 2017-02-07

Similar Documents

Publication Publication Date Title
US20160084572A1 (en) Process control methods for obtaining and maintaining a desired moisture content of spray dried plasma
US20210213057A1 (en) Spray Dried Human Plasma
US8407912B2 (en) Spray dried human plasma
US20220117897A1 (en) Spray-Dried Blood Products and Methods of Making Same
JP4886194B2 (en) Apparatus and method for formulation of autologous thrombin serum
US20060035383A1 (en) Dry platelet preparations for use in diagnostics
WO2014051879A1 (en) Spray drier assembly for automated spray drying
WO2014051878A1 (en) Automated spray drier control system for tracking dried plasma production
US20110183311A1 (en) Dry platelet preparations for use in diagnostics
Adan et al. Autotransfusion of drained mediastinal blood after cardiac surgery: a reappraisal
US10517973B2 (en) Method for the sterilization of chromatographic material and chromatographic material sterilized according to said method
Gunaydin et al. Novel ultrafiltration technique for blood conservation in cardiac operations
Smith et al. Procoagulant phospholipid concentration in canine erythrocyte concentrates stored with or without prestorage leukoreduction
EP3466449B1 (en) Integrated platelet collection and pathogen inactivation processing systems and fluid circuits
US20240091155A1 (en) Pretreatment Of Plasma For Spray Drying And Storage
US20240091156A1 (en) Methods For Making Spray Dried Plasma

Legal Events

Date Code Title Description
AS Assignment

Owner name: VELICO MEDICAL, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KHAN, ABDUL WAHID;WILT, MICHAEL;LUCIEN, RUD KARLY;REEL/FRAME:041122/0942

Effective date: 20161025

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION